<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">66608</article-id><article-id pub-id-type="doi">10.7554/eLife.66608</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title>KSR1- and ERK-dependent translational regulation of the epithelial-to-mesenchymal transition</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-222507"><name><surname>Rao</surname><given-names>Chaitra</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2834-7458</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-222508"><name><surname>Frodyma</surname><given-names>Danielle E</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-222509"><name><surname>Southekal</surname><given-names>Siddesh</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-222510"><name><surname>Svoboda</surname><given-names>Robert A</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-222511"><name><surname>Black</surname><given-names>Adrian R</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-222512"><name><surname>Guda</surname><given-names>Chittibabu</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-222521"><name><surname>Mizutani</surname><given-names>Tomohiro</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-234876"><name><surname>Clevers</surname><given-names>Hans</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-222514"><name><surname>Johnson</surname><given-names>Keith R</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-222515"><name><surname>Fisher</surname><given-names>Kurt W</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-31357"><name><surname>Lewis</surname><given-names>Robert E</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3616-2971</contrib-id><email>rlewis@unmc.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00thqtb16</institution-id><institution>Eppley Institute, University of Nebraska Medical Center</institution></institution-wrap><addr-line><named-content content-type="city">Omaha</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00thqtb16</institution-id><institution>Department of Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center</institution></institution-wrap><addr-line><named-content content-type="city">Omaha</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00thqtb16</institution-id><institution>Department of Pathology and Microbiology, University of Nebraska Medical Center</institution></institution-wrap><addr-line><named-content content-type="city">Omaha</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution>Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW) and UMC Utrecht</institution><addr-line><named-content content-type="city">Utrecht</named-content></addr-line><country>Netherlands</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00thqtb16</institution-id><institution>Department of Oral Biology, University of Nebraska Medical Center</institution></institution-wrap><addr-line><named-content content-type="city">Omaha</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Sonenberg</surname><given-names>Nahum</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01pxwe438</institution-id><institution>McGill University</institution></institution-wrap><country>Canada</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Cooper</surname><given-names>Jonathan A</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/007ps6h72</institution-id><institution>Fred Hutchinson Cancer Research Center</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>10</day><month>05</month><year>2021</year></pub-date><volume>10</volume><elocation-id>e66608</elocation-id><history><date date-type="received" iso-8601-date="2021-01-16"><day>16</day><month>01</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-05-09"><day>09</day><month>05</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Rao et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Rao et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-66608-v3.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-66608-figures-v3.pdf"/><abstract><p>The epithelial-to-mesenchymal transition (EMT) is considered a transcriptional process that induces a switch in cells from a polarized state to a migratory phenotype. Here, we show that KSR1 and ERK promote EMT-like phenotype through the preferential translation of Epithelial-Stromal Interaction 1 (EPSTI1), which is required to induce the switch from E- to N-cadherin and coordinate migratory and invasive behavior. EPSTI1 is overexpressed in human colorectal cancer (CRC) cells. Disruption of KSR1 or EPSTI1 significantly impairs cell migration and invasion in vitro, and reverses EMT-like phenotype, in part, by decreasing the expression of N-cadherin and the transcriptional repressors of E-cadherin expression, ZEB1 and Slug. In CRC cells lacking KSR1, ectopic EPSTI1 expression restored the E- to N-cadherin switch, migration, invasion, and anchorage-independent growth. KSR1-dependent induction of EMT-like phenotype via selective translation of mRNAs reveals its underappreciated role in remodeling the translational landscape of CRC cells to promote their migratory and invasive behavior.</p></abstract><abstract abstract-type="plain-language-summary"><title>eLife digest</title><p>The majority of cancer deaths result from tumor cells spreading to other parts of the body via a process known as metastasis. 90% of all cancers originate in epithelial cells that line the inner and outer surface of organs in our bodies. Epithelial cells, however, are typically stationary and must undergo various chemical and physical changes to transform in to migratory cells that can invade other tissues.</p><p>This transformation process alters the amount of protein cells use to interact with one another. For example, epithelial cells from the colon produce less of a protein called E-cadherin as they transition into migrating cancer cells and make another protein called N-cadherin instead. A protein called KSR1 is a key component of a signaling pathway that is responsible for generating the proteins colon cancer cells need to survive. But it is unknown which proteins KSR1 helps synthesize and whether it plays a role in the metastasis of colon cancer cells.</p><p>To investigate this, Rao et al. studied the proteins generated by cancerous colon cells cultured in the laboratory, in the presence and absence of KSR1. The experiment showed that KSR1 increases the levels of a protein called EPSTI1, which colon cancer cells need to transform into migratory cells. Depleting KSR1 caused cancer cells to generate less EPSTI1 and to share more features with healthy cells, such as higher levels of E-cadherin on their surface and reduced mobility. Adding EPSTI1 to the cancer cells that lacked KSR1 restored the traits associated with metastasis, such as high levels of N-cadherin, and allowed the cells to move more easily.</p><p>These findings suggest that KSR1 and EPSTI1 could be new drug targets for reducing, or potentially reversing, the invasive behavior of colon cancer cells. However, further investigation is needed to reveal how EPSTI1 is generated and how this protein helps colon cancer cells move and invade other tissues.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>Human</kwd><kwd>colon cancer cells</kwd><kwd>human organoids</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>P20 GM121316</award-id><principal-award-recipient><name><surname>Lewis</surname><given-names>Robert E</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>P30 CA036727</award-id><principal-award-recipient><name><surname>Lewis</surname><given-names>Robert E</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>A key Ras-driven signaling pathway stimulates the preferential translation of an effector, EPSTI1, that is both necessary and sufficient for the epithelial-to-mesenchymal transition-like phenotype in colorectal cancer cells.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Molecular scaffolds affect the intensity and duration of signaling pathways by coordinating a discrete set of effectors at defined subcellular locations to regulate multiple cell fates (<xref ref-type="bibr" rid="bib36">Morrison and Davis, 2003</xref>; <xref ref-type="bibr" rid="bib50">Pawson and Scott, 1997</xref>). Kinase Suppressor of Ras 1 (KSR1) serves as a scaffold for Raf, MEK, and ERK enabling the efficient transmission of signals within the mitogen activated protein kinase (MAPK) cascade (<xref ref-type="bibr" rid="bib24">Kortum and Lewis, 2004</xref>; <xref ref-type="bibr" rid="bib40">Nguyen et al., 2002</xref>). Although KSR1 is dispensable for normal development, it is necessary for oncogenic Ras-induced tumorigenesis including colorectal cancer cells (<xref ref-type="bibr" rid="bib24">Kortum and Lewis, 2004</xref>; <xref ref-type="bibr" rid="bib40">Nguyen et al., 2002</xref>; <xref ref-type="bibr" rid="bib14">Fisher et al., 2011</xref>; <xref ref-type="bibr" rid="bib15">Fisher et al., 2015</xref>; <xref ref-type="bibr" rid="bib37">Morrison et al., 2009</xref>; <xref ref-type="bibr" rid="bib54">Rao et al., 2020</xref>), suggesting that KSR1 may modulate aberrant signals that redirect the function of effectors typically involved in normal cellular homeostasis. Activating Ras mutations are present in over 40 % of colorectal cancers (CRC), and associated with advanced disease and decreased overall survival (<xref ref-type="bibr" rid="bib17">Haigis, 2017</xref>; <xref ref-type="bibr" rid="bib62">Serebriiskii et al., 2019</xref>). Activated Ras, a critical driver of both tumor growth and survival, is an alluring therapeutic target, yet targeting the majority of oncogenic Ras alleles is still a work in progress. Raf/MEK/ERK signaling can phenocopy Ras signaling essential for CRC growth and survival (<xref ref-type="bibr" rid="bib61">Schmitz et al., 2007</xref>; <xref ref-type="bibr" rid="bib5">Brandt et al., 2019</xref>). Therefore, understanding the effectors that transmit signals emanating from oncogenic Ras is a valuable step in detecting and targeting the pathways critical to tumor cell function and their adaptation to therapy.</p><p>Oncogene-driven signaling pathways promote mRNA translation that enables expression of a subset of mRNAs to promote growth, invasion, and metastasis (<xref ref-type="bibr" rid="bib7">Chu et al., 2016</xref>; <xref ref-type="bibr" rid="bib4">Avdulov et al., 2004</xref>; <xref ref-type="bibr" rid="bib72">Truitt Morgan et al., 2015</xref>; <xref ref-type="bibr" rid="bib51">Pelletier et al., 2015</xref>). Tumor cells have an increased dependence on cap-dependent translation, unlike their normal complements (<xref ref-type="bibr" rid="bib72">Truitt Morgan et al., 2015</xref>; <xref ref-type="bibr" rid="bib71">Truitt and Ruggero, 2016</xref>). Eukaryotic Translation Initiation Factor 4E (eIF4E) is a rate-limiting factor for oncogenic transformation, with reductions of as little as 40 % being sufficient to block tumorigenesis (<xref ref-type="bibr" rid="bib72">Truitt Morgan et al., 2015</xref>). eIF4E function is regulated by association of 4E-binding proteins (4EBPs). Importantly, disruption of KSR1 or ERK inhibition leads to dephosphorylation and activation of 4EBP1, indicating that the function of KSR1 as an ERK scaffold is key to the aberrant regulation of mRNA translation (<xref ref-type="bibr" rid="bib34">McCall et al., 2016</xref>). This tumor-specific, KSR1-dependent regulation of mRNA translation of a subset of genes was predicted to selectively promote survival of CRC cells but not normal colon epithelia (<xref ref-type="bibr" rid="bib34">McCall et al., 2016</xref>; <xref ref-type="bibr" rid="bib39">Neilsen et al., 2019</xref>).</p><p>Almost all CRC originates from epithelial cells lining the colon or rectum of the gastrointestinal tract, but in order to invade to the surrounding tissue, cancer cells lose cell adhesiveness to acquire motility and become invasive, characterized by the epithelial-to-mesenchymal transition (EMT), which is central to tumor pathogenesis (<xref ref-type="bibr" rid="bib78">Ye and Weinberg, 2015</xref>; <xref ref-type="bibr" rid="bib43">Nieto, 2013</xref>; <xref ref-type="bibr" rid="bib69">Thiery et al., 2009</xref>; <xref ref-type="bibr" rid="bib12">Dongre and Weinberg, 2019</xref>). EMT involves a complex cellular process during which epithelial cells lose polarity, cell-cell contacts and acquire mesenchymal characteristics. While EMT is crucial for cell plasticity during embryonic development, trans differentiation and wound healing, when aberrantly activated EMT has deleterious effects, which facilitate motility and invasion of cancer cells (<xref ref-type="bibr" rid="bib43">Nieto, 2013</xref>; <xref ref-type="bibr" rid="bib69">Thiery et al., 2009</xref>; <xref ref-type="bibr" rid="bib12">Dongre and Weinberg, 2019</xref>; <xref ref-type="bibr" rid="bib44">Nieto et al., 2016</xref>). EMT has been shown to be controlled by transcription-dependent mechanisms, especially through repression of genes that are hallmarks of epithelial phenotype such as E-cadherin. Loss of E-cadherin at the membrane has been associated with carcinoma progression and EMT (<xref ref-type="bibr" rid="bib69">Thiery et al., 2009</xref>; <xref ref-type="bibr" rid="bib68">Thiery, 2002</xref>; <xref ref-type="bibr" rid="bib45">Oda et al., 1994</xref>; <xref ref-type="bibr" rid="bib16">Frixen et al., 1991</xref>). E-cadherin function is transcriptionally repressed through the action of EMT transcription factors (TFs), including Snail-family proteins (<italic>Snail1</italic>, <italic>Slug</italic>), zinc finger E-box binding homeobox 1 and 2 (<italic>ZEB1</italic> and <italic>ZEB2</italic>), and twist-related protein (<italic>Twist</italic>) (<xref ref-type="bibr" rid="bib44">Nieto et al., 2016</xref>; <xref ref-type="bibr" rid="bib21">Jolly et al., 2017</xref>). Transcriptional control of E-cadherin is unlikely to be sole determinant of EMT, invasion and metastasis. Inappropriate induction of non-epithelial cadherins, such as N-cadherin by epithelial cells are known to play a fundamental role during initiation of metastasis (<xref ref-type="bibr" rid="bib42">Nieman et al., 1999</xref>; <xref ref-type="bibr" rid="bib29">Liu et al., 2017</xref>; <xref ref-type="bibr" rid="bib67">Suyama et al., 2002</xref>; <xref ref-type="bibr" rid="bib56">Rosivatz et al., 2004</xref>; <xref ref-type="bibr" rid="bib47">Okubo et al., 2017</xref>; <xref ref-type="bibr" rid="bib58">Sadot et al., 1998</xref>; <xref ref-type="bibr" rid="bib30">Loh et al., 2019</xref>). N-cadherin disassembles adherent junction complexes, disrupting the intercellular cohesion and reorienting the migration of cells, away from the direction of cell-cell contact (<xref ref-type="bibr" rid="bib42">Nieman et al., 1999</xref>; <xref ref-type="bibr" rid="bib59">Scarpa et al., 2015</xref>). Upregulation of N-cadherin expression promotes motility and invasion (<xref ref-type="bibr" rid="bib42">Nieman et al., 1999</xref>; <xref ref-type="bibr" rid="bib29">Liu et al., 2017</xref>; <xref ref-type="bibr" rid="bib67">Suyama et al., 2002</xref>; <xref ref-type="bibr" rid="bib18">Hulit et al., 2007</xref>). Thus, central to the process of EMT is the coordinated loss of E-cadherin expression and the upregulation of N-cadherin gene expression, termed cadherin switching (<xref ref-type="bibr" rid="bib30">Loh et al., 2019</xref>; <xref ref-type="bibr" rid="bib76">Wheelock et al., 2008</xref>; <xref ref-type="bibr" rid="bib70">Tomita et al., 2000</xref>; <xref ref-type="bibr" rid="bib33">Maeda et al., 2005</xref>; <xref ref-type="bibr" rid="bib3">Araki et al., 2011</xref>).</p><p>Previous studies have demonstrated transcriptional regulation of EMT through oncogenic Ras or its downstream effector signaling pathways via the activation of EMT-TFs (<xref ref-type="bibr" rid="bib63">Shin et al., 2010</xref>; <xref ref-type="bibr" rid="bib64">Shin et al., 2019</xref>; <xref ref-type="bibr" rid="bib2">Andreolas et al., 2008</xref>; <xref ref-type="bibr" rid="bib28">Liu et al., 2014</xref>; <xref ref-type="bibr" rid="bib77">Wong et al., 2013</xref>; <xref ref-type="bibr" rid="bib75">Wang et al., 2010</xref>; <xref ref-type="bibr" rid="bib26">Lemieux et al., 2009</xref>). Oncogenic Ras itself activates EMT-TF <italic>Slug</italic> to induce EMT in skin and colon cancer cells (<xref ref-type="bibr" rid="bib77">Wong et al., 2013</xref>; <xref ref-type="bibr" rid="bib75">Wang et al., 2010</xref>). Enhanced activity of ERK2 but not ERK1, has been linked with Ras-dependent regulation of EMT (<xref ref-type="bibr" rid="bib63">Shin et al., 2010</xref>; <xref ref-type="bibr" rid="bib64">Shin et al., 2019</xref>). Several studies have also described an alternative program wherein cells lose their epithelial phenotype, via post-transcriptional modifications rather than transcriptional repression involving translational regulation or protein internalization (<xref ref-type="bibr" rid="bib19">Jechlinger et al., 2003</xref>; <xref ref-type="bibr" rid="bib1">Aiello et al., 2018</xref>; <xref ref-type="bibr" rid="bib74">Waerner et al., 2006</xref>). Expression profiling of polysome-bound mRNA to assess translational efficiency identified over 30 genes that were translationally regulated upon Ras and <italic>TGFβ</italic> inducing EMT (<xref ref-type="bibr" rid="bib19">Jechlinger et al., 2003</xref>; <xref ref-type="bibr" rid="bib74">Waerner et al., 2006</xref>). Functional characterization of the resultant proteins should reveal preferentially translated mRNAs essential to invasion and metastasis.</p><p><italic>EPSTI1</italic> was identified as a stromal fibroblast-induced gene upon co-cultures of breast cancer cells with stomal fibroblasts (<xref ref-type="bibr" rid="bib41">Nielsen et al., 2002</xref>). EPSTI1 is expressed at low levels in normal breast and colon tissue but aberrantly expressed in breast tumor tissue (<xref ref-type="bibr" rid="bib41">Nielsen et al., 2002</xref>). EPSTI1 promotes cell invasion and malignant growth of primary breast tumor cells (<xref ref-type="bibr" rid="bib27">Li et al., 2014</xref>; <xref ref-type="bibr" rid="bib8">de Neergaard et al., 2010</xref>). We performed polysome profiling in CRC cells and found that KSR1- and ERK induces of EPSTI1 mRNA translation. EPSTI1 is both necessary and sufficient for coordinating the upregulation of N-cadherin with the downregulation of E-cadherin to stimulate cell motility and invasion in colon cancer cells. These data demonstrate that ERK-regulated regulation of mRNA translation is an essential contributor to EMT-like phenotype and reveal a novel effector of the cadherin switch whose characterization should yield novel insights into the mechanisms controlling the migratory and invasive behavior of cells.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Genome-wide polysome profiling reveals translational regulation of EPSTI1 by KSR1</title><p>ERK signaling regulates global and selective mRNA translation through RSK1/2-dependent modification of cap-dependent translation (<xref ref-type="bibr" rid="bib34">McCall et al., 2016</xref>; <xref ref-type="bibr" rid="bib57">Roux et al., 2007</xref>). Phosphorylation of cap binding protein 4E-BP1 releases eIF4E to promote translation and the abundance of eIF4E is a rate-limiting factor for oncogenic Ras- and Myc-driven transformation (<xref ref-type="bibr" rid="bib72">Truitt Morgan et al., 2015</xref>). We showed previously that KSR1 maximizes ERK activation in the setting of oncogenic Ras (<xref ref-type="bibr" rid="bib25">Kortum et al., 2006</xref>), which is required for increased Myc translation via dephosphorylation of 4E-BP1, supporting CRC cell growth (<xref ref-type="bibr" rid="bib34">McCall et al., 2016</xref>). These observations imply that the ERK scaffold function of KSR1 alters the translational landscape in CRC cells to support their survival.</p><p>To determine the effect of KSR1 on translatomes in colon cancer cells, we performed genome-wide polysome profiling (<xref ref-type="bibr" rid="bib23">King and Gerber, 2016</xref>). We stably expressed short hairpin RNA (shRNA) constructs targeting KSR1 (KSR1 RNAi) or a non-targeting control in two K-Ras mutant CRC cell lines, HCT116 and HCT15 (<xref ref-type="fig" rid="fig1">Figure 1D</xref>, top panels). We isolated and quantified both total mRNA and efficiently translated mRNAs (associated with ≥3 ribosomes) using RNA sequencing (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). We used Anota2seq (<xref ref-type="bibr" rid="bib46">Oertlin et al., 2019</xref>) to calculate translation efficiency (TE) by comparing the differences in efficiently translated mRNAs to the total transcript of each mRNA and observed that a significant number of mRNAs ([selDeltaTP ≥ log (1.2) and selDeltaPT ≥ log (1.2)] and p-value &lt; 0.05) showed either reduced TE or upregulated TE upon KSR1 disruption (<xref ref-type="fig" rid="fig1">Figure 1B, C</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>, <xref ref-type="supplementary-material" rid="sdata1">Source data 1</xref>) in both HCT116 and HCT15 cells. Gene Set Enrichment Analysis (GSEA) (<xref ref-type="bibr" rid="bib66">Subramanian et al., 2005</xref>) of significantly enriched genes in HCT116 and HCT15 (<xref ref-type="fig" rid="fig1">Figure 1B</xref>, <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A, B</xref>), identified 11 mRNAs in the gene set titled “Hallmark EMT signature”, “Jechlinger EMT Up”, and “Gotzmann EMT up” , that had significantly decreased translation upon KSR1 disruption (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). Among the genes with decreased translation, <italic>EPSTI1</italic> was one of the highly significant mRNAs. We sought to determine the functional relevance of KSR1-dependent induction of EPSTI1 to phenotypic plasticity in colon cancer cells.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>EPSTI1 translation is regulated by KSR1.</title><p>(<bold>A</bold>) Representative polysome profiles from control and KSR1 knockdown (KSR1 RNAi) HCT116 and HCT15 cells. Sucrose gradient fractions 3–5 denote the low-molecular-weight complexes (monosomes) and the fractions 6–8 are the high-molecular-weight complexes (polysomes). (<bold>B</bold>) Scatter plot of polysome-associated mRNA to total mRNA log2 fold-changes upon KSR1 knockdown in HCT116 and HCT15 with RNA-seq. The statistically significant genes in the absence of KSR1 are classified into four groups with a fold change (|log<sub>2</sub>FC|) &gt; 1.2 and p-value &lt; 0.05. The number of mRNAs with a change in TE (orange and red) are indicated (n = 3 for each condition). TE, translational efficiency. (<bold>C</bold>) Heatmap of TE changes for the top 40 RNAs control and KSR1 knockdown (KSR1 RNAi) HCT116 and HCT15 cells (n = 3 for each condition). (<bold>D</bold>) Western blot analysis of KSR1 and EPSTI1 following KSR1 knockdown in HCT116 and HCT15 cells. (<bold>E</bold>) RT-qPCR analysis of EPSTI1 mRNA from total RNA and polysomal RNA (fractions number 6–8) in control and KSR1 knockdown HCT116 and HCT15 cells, the TE was calculated as the ratio of polysomal mRNA to the total mRNA (n = 3; *, p &lt; 0.05). (<bold>F</bold>) RT-qPCR analysis of <italic>EPSTI1</italic> mRNA levels isolated from sucrose gradient fractions of the control and KSR1 knockdown HCT116 and HCT15 cells. Fractions 3–5 (low MW) and 6–8 (high MW) are plotted for the control and KSR1 knockdown state with values corresponding to the percentage of total mRNA across these fractions n = 3. Experiments shown in (<bold>A–F</bold>) are representative of three independent experiments.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-66608-fig1-v3.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Three independent replicates of the polysome profiles from control and KSR1 knockdown (shKSR1) HCT116 and HCT15 cells.</title><p><xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A</xref> and 1B were used as representative images for <xref ref-type="fig" rid="fig1">Figure 1A</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-66608-fig1-figsupp1-v3.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>EPSTI1 is translationally regulated by KSR1.</title><p>(<bold>A</bold>) Scatter plot of polysome-associated mRNA to total mRNA log2 fold-changes upon KSR1 knockdown in HCT116 (top) and HCT15 (bottom) with RNA-seq. The statistically significant genes in the absence of KSR1 are classified into four groups with a fold change (|log<sub>2</sub>FC| &gt; 1.2) and p-value &lt; 0.05. The number of mRNAs with a change in TE (orange and red) are indicated (n = 3 for each cell line). TE, translational efficiency (<bold>B</bold>) Differential gene expression analysis comparing genes whose TE is changed upon KSR1- knockdown in HCT116 and HCT15 (<bold>C</bold>) RT-qPCR analysis of <italic>HPRT</italic> mRNA levels isolated from sucrose gradient fractions of the control and KSR1 knockdown HCT116 and HCT15 cells. Fractions 3–5 (low MW) and 6–8 (high MW) are plotted for the control and KSR1 knockdown state with values corresponding to the percentage of total mRNA across these fractions. Experiments shown in (<bold>A–C</bold>) are representative of three independent experiments. (<bold>D</bold>) EPSTI1 and KSR1 levels were assessed by western blot following treatment with cycloheximide (CHX) for 0, 2, 4, and 6 hr in HCT116 cells. (<bold>E</bold>) Representative western blot images showing HCT116 control and KSR1 CRISPR cells treated with DMSO or 10 µM of MG132 for 6 hours in the presence or absence of 10 µM of CHX for 6 hr and levels of KSR1 or EPSTI1 protein were revealed by western blot. Experiments shown in (<bold>D–E</bold>) are representative of at least two independent experiments.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-66608-fig1-figsupp2-v3.tif"/></fig></fig-group><p>To confirm that EPSTI1 translation is KSR1-dependent, we observed that, EPSTI1 protein expression was decreased with the knockdown of KSR1 in HCT116 and HCT15 cells (<xref ref-type="fig" rid="fig1">Figure 1D</xref>), while the total mRNA transcript was unchanged upon KSR1 disruption (<xref ref-type="fig" rid="fig1">Figure 1E</xref>, left panel). <italic>EPSTI1</italic> TE was markedly decreased upon KSR1 depletion (<xref ref-type="fig" rid="fig1">Figure 1E</xref>, right). RT-qPCR analysis of sucrose-gradient fractions of monosome mRNA and polysome RNA distribution confirmed that <italic>EPSTI1</italic> mRNA shifted from actively translating high-molecular-weight (MW) polysome fractions to low-MW fractions in KSR1 knockdown cells (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). In contrast, <italic>HPRT1</italic> mRNA was insensitive to KSR1 knockdown in HCT116 and HCT15 cells, and qPCR analysis of <italic>HPRT1 mRNA</italic> isolated from sucrose gradient fractions of control and KSR1 knockdown cells showed no significant shift between the low-MW and the high-MW fractions (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2C</xref>). To determine if KSR1 promotes EPSTI1 degradation, we first assessed EPSTI1 turnover in HCT116 cells following treatment with a protein-synthesis inhibitor, cycloheximide (CHX) and observed that EPSTI1 has a 6 hr half-life (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2D</xref>). We analyzed EPSTI1 turnover using a combination of proteasome inhibitor, MG132 and CHX in control and CRISPR-targeted KSR1 HCT116 cells (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2E</xref>). EPSTI1 turnover was not sensitive to MG132 treatment in HCT116 cells lacking KSR1 expression. Therefore, in HCT116 cells, KSR1 does not mediate ubiquitin proteosome system (UPS)-mediated degradation of EPSTI1. These data support our conclusion that EPSTI1 translation is induced by KSR1.</p></sec><sec id="s2-2"><title>KSR1/ERK signaling regulates EPSTI1 expression in colon cancer cells</title><p>To confirm our observations in KSR1 knockdown cells, we tested the effect of CRISPR/Cas9-mediated targeting of KSR1 on EPSTI1 in CRC cell lines. EPSTI1 protein expression was decreased upon KSR1 depletion in HCT116 and HCT15 cells and EPSTI1 expression was restored in knockout cells upon expression of a KSR1 transgene (+ KSR1) (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Similar to inhibition of KSR1, treatment with ERK inhibitor SCH772984 (<xref ref-type="bibr" rid="bib35">Morris et al., 2013</xref>) suppressed EPSTI1 protein expression in both CRC cell line HCT116 and tumorigenic patient derived colon organoid engineered with deletion of APC, p53, SMAD4, and K-Ras<sup>G12D</sup> mutation (PDO-11 AKPS) (<xref ref-type="fig" rid="fig2">Figure 2B</xref>; <xref ref-type="bibr" rid="bib13">Drost et al., 2015</xref>). To determine if EPSTI1 expression is also dependent on mTOR signaling, we tested the effect of mTOR inhibition on EPSTI1expression. Though mTOR inhibitor, AZD8055 (<xref ref-type="bibr" rid="bib6">Chresta et al., 2010</xref>) robustly inhibited phosphorylation of mTOR substrate p70 S6 kinase, its ability to decrease EPSTI1 expression in HCT116 cells was weak relative to treatment with the ERK inhibitor (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). These observations suggest the ERK affects EPSTI1 expression via mechanisms distinct from mTOR. While the total protein was reduced upon ERK inhibition in HCT116, the <italic>EPSTI1</italic> transcript levels were not altered significantly by SCH772984 treatment (<xref ref-type="fig" rid="fig2">Figure 2D</xref>).</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>KSR1 or ERK inhibition suppresses EPSTI1 protein expression in cell lines and organoids.</title><p>(<bold>A</bold>) Cell lysates prepared from control, KSR1 CRISPR-targeted (KSR1 CRISPR) and CRISPR-targeted HCT116 and HCT15 cells expressing KSR1 (KSR1 CRISPR+ KSR1) analyzed for EPSTI1 protein expression by western blotting. (<bold>B</bold>) Western blot of the indicated proteins in HCT116 (left) and AKPS quadruple mutant organoids (right) treated with DMSO or 1 µM of SCH772984 for 48 hr. (<bold>C</bold>) EPSTI1 protein expression was analyzed by western blot in HCT116 cells treated with DMSO, 1 µM of SCH772984, or 1 µM of AZD8055 for 48 hr. (<bold>D</bold>) RT-qPCR analysis of <italic>EPSTI1</italic> mRNA from total RNA in HCT116 cells treated with either DMSO or ERK1/2 selective inhibitor, SCH772984 (n = 3; ns, non-significant). (<bold>E</bold>) Representative polysome profiles from HCT116 cells treated DMSO or 1 µM of ERK1/2 selective inhibitor, SCH772984. (<bold>F</bold>) RT-qPCR analysis of <italic>EPSTI1</italic> and <italic>HPRT1</italic> mRNA levels from LMW (fractions 3–5) and HMW (fractions 6–8) of the DMSO control or SCH772984-treated HCT116 cells (n = 3; *, p &lt; 0.05; ***, p &lt; 0.001). All values displayed as mean ± S.D. Experiments shown in (<bold>A–F</bold>) are representative of three independent experiments.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-66608-fig2-v3.tif"/></fig><p>We performed polysome profiling in HCT116 cells, either treated with DMSO or ERK inhibitor, SCH772984 and we isolated mRNA from low-MW monosome (fractions 3–5) and high-MW polysome (fractions 6–8) fractions (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). RT-qPCR demonstrated that <italic>EPSTI1</italic> mRNA shifted from high-MW fractions to the low-MW fractions upon ERK inhibition (<xref ref-type="fig" rid="fig2">Figure 2F</xref>). The distribution of mRNA for <italic>HPRT1</italic> within the same profile was not altered by SCH772984 treatment (<xref ref-type="fig" rid="fig2">Figure 2F</xref>). These data indicate that KSR1-dependent ERK signaling is a critical regulator of EPSTI1 mRNA translation in colon cells and organoids.</p></sec><sec id="s2-3"><title>EPSTI1 is required for anchorage-independent growth in colon cancer cells</title><p>KSR1 disruption inhibits HCT116 cell anchorage-independent growth in vitro and tumor formation in vivo (<xref ref-type="bibr" rid="bib15">Fisher et al., 2015</xref>). Similarly, disruption of KSR1 by CRISPR/Cas9-mediated targeting decreased HCT116 and HCT15 cell viability under anchorage-independent conditions on simulated by poly-(HEMA) coating (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). KSR1 transgene expression restored cell viability in HCT116 and HCT15 cells lacking KSR1 (KSR1 CRISPR+ KSR1) (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). We showed previously that KSR1 expression is upregulated in colon cancer cell lines when compared to the non-transformed human colon epithelial cells (HCECs) (<xref ref-type="bibr" rid="bib15">Fisher et al., 2015</xref>). We observed that EPSTI1 protein is aberrantly expressed in colon cancer cell lines HCT116 and HCT15, while its expression is detected weakly in HCECs (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). EPSTI1 protein expression is also markedly higher in AKPS organoids than normal colon organoids (<xref ref-type="fig" rid="fig3">Figure 3B</xref>).</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>EPSTI1 is overexpressed in cancer cell lines and organoids and promotes anchorage-independent growth.</title><p>(<bold>A</bold>) Anchorage-independent cell viability was analyzed in HCT116 and HCT15 cells plated on poly-(HEMA)-coated plates was measured using CellTiter-Glo following CRISPR-targeting (KSR1 CRISPR) and re-expressing KSR1 (KSR1 CRISPR+ KSR1) in the CRISPR-targeted cells. The data are shown as relative luminescence units mean ± SD, n = 6. Matched results were analyzed for statistical significance one-way ANOVA followed by t-test. (Upper panels) Western blot showing the expression of KSR1 in control, KSR1 knockout and KSR1-knockout cells expressing a KSR1 transgene (+ KSR1). (<bold>B</bold>) Western blot analysis of EPSTI1 protein expression was assessed in HCECs, HCT116, HCT15, normal human colon organoids, and transformed AKPS colon organoids. (<bold>C</bold>) Viability of HCT116 and HCT15 cells measured using CellTiter-Glo following siRNA knockdown of EPSTI1 that were plated on poly-(HEMA)-coated plates to simulate anchorage-independent conditions. Cell viability was measured immediately after plating and 0, 1, and 3 days after plating (n = 6). The data are shown as mean luminescence units ± SD. Matched results were analyzed for statistical significance by t-test. (Top) Western blot confirming the knockdown of EPSTI1 in HCT116 and SW480 at Day 3. (<bold>D</bold>) (Left) Quantification of the colonies formed in HCT116 and SW480 cells following RNAi knockdown using non-targeting control (siCON) or EPSTI1 (siEPSTI1) after plating on soft agar. (Right) Representative photomicrographs of colonies for each sample. The data are illustrated as the number of colonies present after 2 weeks, mean ± SD, n = 6. Paired results were analyzed for statistical significance using Student’s <italic>t</italic> test. (Top) Western blot confirming the knockdown of EPSTI1 in HCT116 and SW480 cells. ****, p &lt; 0.0001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-66608-fig3-v3.tif"/></fig><p>To determine the regulation of EPSTI1 in human colon tumor maintenance, we performed siRNA knockdown of EPSTI1 in HCT116 and HCT15 cells. EPSTI1 disruption suppressed viability on poly-(HEMA) coated by 40 % in HCT15 cells, and over 70%, in HCT116 cells (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). EPSTI1 knockdown reduced colony formation in soft agar by 63 % in HCT116 cells and 71 % in SW480 cells (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). These observations show that KSR1-dependent translation of ESPTI1 is required for anchorage-independent growth of colon tumor cell lines.</p></sec><sec id="s2-4"><title>KSR1 or EPSTI1 disruption decreases cell mobility in CRC cells</title><p>Considering the suggested role of EPSTI1 in promoting EMT-like phenotypes (<xref ref-type="bibr" rid="bib41">Nielsen et al., 2002</xref>; <xref ref-type="bibr" rid="bib27">Li et al., 2014</xref>), we sought to evaluate the biological role of EPSTI1 in colon cancer cells. Time-lapse images of control and EPSTI1 knockdown in HCT116 cell motility in a scratch wound was analyzed by measuring the relative wound density (<xref ref-type="bibr" rid="bib20">Johnston et al., 2015</xref>) over 72 hours (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, bottom). IncuCyte software was used to calculate relative wound density, that is, the percentage of spatial cell density inside the wound relative to the spatial density outside of the wound area at a given time point. The calculation of cell migration using this method, avoids false changes in cell density due to proliferation. Motility was also assessed in control, CRISPR-targeted (KSR1 CRISPR), and CRIPSR-targeted HCT116 cells expressing KSR1 (KSR1 CRISPR+ KSR1) (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, top). Cells lacking either EPSTI1 or KSR1 were approximately 20 % less motile compared to control cells. Reintroduction of KSR1 expression in CRISPR-targeted HCT116 cells restored motility comparable to the control cells (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, top).</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>KSR1 or EPSTI1 promote migration and invasion in CRC cells.</title><p>(<bold>A</bold>) Control, CRISPR-targeted (KSR1 CRISPR) and CRISPR-targeted HCT116 cells expressing KSR1 (KSR1 CRISPR+ KSR1) (upper) and control or EPSTI1 knockdown HCT116 cells (lower) were evaluated in a 96-well IncuCyte scratch wound assay. The graph represents the time kinetics of percent wound density, calculated by IncuCyte ZOOM software, shown as mean ± SD, n = 12 ****, p &lt; 0.0001. Matched results were analyzed for statistical significance using one-way ANOVA with Dunnett’s posttest for multiple comparisons. (<bold>B</bold>) (Upper panels) Control, KSR1 knockout (KSR1 CRISPR), and EPSTI1 knockdown (siEPSTI1) were subjected to Transwell migration assay through Matrigel for 24 hr using 10 % FBS as chemoattractant. The number of invaded cells per field were counted. Data are the mean ± SD (n = 6); *, p &lt; 0.1; **, p &lt; 0.01; ***, p &lt; 0.001. (Lower panels) Representative images of Giemsa-stained cells 24 hr after invasion through Matrigel.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-66608-fig4-v3.tif"/></fig><p>EPSTI1 knockdown HCT116 and SW480 cells were subjected to Transwell invasion assays. EPSTI1 RNAi suppresses cell invasion through Matrigel by 72 % in HCT116 and by 75 % in SW480. (<xref ref-type="fig" rid="fig4">Figure 4B</xref>, top right and bottom). Since KSR1 is required for EPSTI1 translation, we determined the functional contribution of KSR1 in regulating cell invasion. KSR1 depletion suppressed invasion by 64 % in HCT116 and by 53 % SW480 cells (<xref ref-type="fig" rid="fig4">Figure 4B</xref>, top left and bottom). Overall, these results suggest the KSR1-dependent EPSTI1 signaling contributes to cell migration and invasion in CRC cells.</p></sec><sec id="s2-5"><title>KSR1 or EPSTI1 disruption causes cadherin switching in CRC cells</title><p>To understand the underlying mechanism by which KSR1 or EPSTI1 promote motility and invasion in CRC cells, we evaluated their contribution to the expression of critical determinants of EMT that modulate cell adhesion, E- and N-cadherins and EMT-TFs. Compared to the non-targeting control, KSR1 disruption in HCT116, HCT15 and SW480 cells had elevated levels of E-cadherin, along with a coincident decrease in EMT-TF Slug (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Expression of Vimentin, and Snail1 was not changed in HCT116 cells (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>). Upon knockdown of EPSTI1 with either of two siRNA oligos, we observed a decrease in the expression of N-cadherin, ZEB1 and Slug. Coincident with the decrease in EMT-TFs, E-cadherin levels were elevated (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). While there was no significant change in the Slug and ZEB1 mRNA upon EPSTI1 knockdown (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>), EPSTI1 disruption decreased N-cadherin mRNA expression over 50 % in HCT116 and SW480 cells (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). Following EPSTI1 knockdown, we subjected control HCT116 cells and HCT116 cells overexpressing N-cadherin to Transwell invasion assay through Matrigel. EPSTI1 knockdown suppressed cell invasion. The expression of N-cadherin in cells lacking EPSTI1 was sufficient to restore invasiveness to HCT116 cells (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C, D</xref>). This is consistent with previous observations that upregulation of N-cadherin expression enhances motility in multiple cancer cell lines (<xref ref-type="bibr" rid="bib42">Nieman et al., 1999</xref>; <xref ref-type="bibr" rid="bib18">Hulit et al., 2007</xref>; <xref ref-type="bibr" rid="bib38">Mrozik et al., 2018</xref>). These results indicate that the switch of E-cadherin to N-cadherin expression promotes the progression of migratory and invasive behavior orchestrated by EPSTI1 signaling in CRC cells.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>KSR1 and EPSTI1 promote cadherin switching.</title><p>(<bold>A</bold>) Western blot analysis of the cell lysates prepared from control, and two clones of CRISPR-targeted HCT116, SW480, and HCT15 cells (KSR1 CRISPR) for the E-cadherin, Slug, and EPSTI1. (<bold>B</bold>) Western blot of ZEB1, Slug, E-cadherin, and N-cadherin in HCT116 and SW480 cells 72 hr following EPSTI1 knockdown. (<bold>C</bold>) RT-qPCR analysis of EPSTI1 mRNA (upper) and N-cadherin (lower) following knockdown of EPSTI1 for 72 hr in HCT116 and SW480 cells. n = 6; ***, p &lt; 0.001; ****, p &lt; 0.0001. Western blots shown in (<bold>A</bold>) and (<bold>B</bold>) and qPCR shown in (<bold>C</bold>) are representative of at least three independent experiments.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-66608-fig5-v3.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>KSR1 and EPSTI1 promote the cadherin switch.</title><p>(<bold>A</bold>) Western blot analysis of the cell lysates prepared from control, and two clones of CRISPR-targeted HCT116 (KSR1 CRISPR) for (Top- upper) E-cadherin and Vimentin, and (bottom-lower) Cell lysates prepared from control, CRISPR-targeted (KSR1 CRISPR) and CRISPR-targeted HCT116 cells expressing KSR1 (MSCV-KSR1) analyzed for Slug and Snail. (<bold>B</bold>) RT-qPCR analysis of Slug mRNA (top-upper) and ZEB1 (bottom-lower) following knockdown of EPSTI1 for 72 hr in HCT116 and SW480 cells. (<bold>C</bold>) (Upper panels) Control, EPSTI1 knockdown (siEPSTI1) with and without N-cadherin over-expression (N-cadherin OE) were subjected to Transwell migration assay through Matrigel for 24 hr using 10 % FBS as chemoattractant. The number of invaded cells per field were counted. Data are the mean ± SD (n = 4); ***, p &lt; 0.001. (Lower panels) Representative images of Giemsa-stained cells 24 hr after invasion through Matrigel. (<bold>D</bold>) Western blot analysis of EPSTI1 and N-cadherin from control and EPSTI1 knockdown cell lysates with and without N-cadherin OE. Experiments are representative of at least two independent experiments.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-66608-fig5-figsupp1-v3.tif"/></fig></fig-group></sec><sec id="s2-6"><title>EPSTI1 is necessary and sufficient for EMT-like phenotype in CRC cells</title><p>To determine the extent to which KSR1- and ERK-dependent EPSTI1 translation is critical to colon tumor cell growth and invasion, we expressed a MSCV-FLAG-EPSTI1-GFP construct in KSR1-CRISPR knockout HCT116, SW480, and HCT15 cells. CRISPR/Cas9-mediated deletion of KSR1 disrupted EPSTI1 expression, downregulated Slug and N-cadherin expression and elevated E-cadherin expression (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). E-cadherin staining was absent in control CRC cells but evident at the cell membrane in KSR1 knockout cells (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). Exogenous expression of EPSTI1 in cells lacking KSR1 restored the cadherin switch, by decreasing the expression of E-cadherin (<xref ref-type="fig" rid="fig6">Figure 6A, B</xref>) and increasing N-cadherin levels comparable to control cells (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). Suppression of E-cadherin and restoration of N-cadherin expression by the EPSTI1 transgene reestablished the ability of KSR1 knockout cells to migrate in monolayer culture (<xref ref-type="fig" rid="fig6">Figure 6C</xref>) and invade through Matrigel. Forced expression of EPSTI1 in these cells, increased the number of invading cells by over threefold (<xref ref-type="fig" rid="fig6">Figure 6D</xref>). To determine the effect of EPSTI1 on cell proliferation, we analyzed the cell growth kinetics in HCT116 and SW480 cells (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). Over 3 days, EPSTI1 knockdown had no effect on cell proliferation compared to control HCT116 and SW480 cells. While EPSTI1 expression in KSR1 knockout cells had no significant effect on cell proliferation for 24 hr in HCT116 and SW480 cells (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A, B</xref>), EPSTI1 expression increased the number of invading cells in that period over 50 % in HCT116 and over 70 % in SW480 cells (<xref ref-type="fig" rid="fig6">Figure 6D</xref>). Although, EPSTI1 expression has a significant effect on cell proliferation over 7 days compared to KSR1 knockout cells in HCT116 and SW480 cells, EPSTI1 expression rescued migratory potential by over 60 % in KSR1-depleted HCT116 and SW480 cells within 24 hr (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). These data reveal that disabling the cadherin switch and inhibition of cell invasion by KSR1 disruption interrupts EPSTI1 translation, highlighting the pivotal role of this pathway for the induction of EMT-like phenotype in CRC cells.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>EPSTI1 rescues cadherin switching and invasive behavior to KSR1 knockout cells.</title><p>(<bold>A</bold>) EPSTI1 protein expression was assessed by western blotting in control, KSR1-targeted (KSR1 CRISPR) HCT116, SW480, and HCT15 cells with and without EPSTI1 (FLAG-EPSTI1) expression. Cells were lysed and probed for Slug, E-cadherin, N-cadherin, Lamin β2, and β actin. (<bold>B</bold>) Immunofluorescence staining for E-cadherin (Red) and DAPI (blue) in control or KSR1-targeted (KSR1 CRISPR) HCT116, SW480, and HCT15 cells with and without EPSTI1 (FLAG-EPSTI1) expression. (<bold>C</bold>) Control, CRIPSR- targeted (KSR1-CRISPR), and CRISPR-targeted HCT116 and SW480 cells expressing EPSTI1 (KSR1 CRISPR+ FLAG-EPSTI1) were subjected to the 96-well IncuCyte scratch wound assay. The graph represents the time kinetics of percent wound density, calculated by IncuCyte ZOOM software, shown as mean ± SD, n = 12; **, p &lt; 0.005; ***, p &lt; 0.001; ****, p &lt; 0.0001. Matched results were analyzed for statistical significance using one-way ANOVA with Dunnett’s posttest for multiple comparisons. (<bold>D</bold>) Control, CRISPR-targeted (KSR1 CRISPR), and CRISPR-targeted HCT116 and SW480 cells expressing EPSTI1 (KSR1 CRISPR+ FLAG-EPSTI1) were subjected to Transwell migration assay through Matrigel . The number of invaded cells per field were counted, (n = 4); ****, p &lt; 0.0001. Representative microscopic images of the respective cells following invasion through Matrigel are shown.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-66608-fig6-v3.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>EPSTI1 rescues cadherin switching and invasive behavior to KSR1 knockout cells.</title><p>Cell proliferation growth curves in control (blue), KSR1 CRISPR (red) HCT116 (<bold>A</bold>) and SW480 (<bold>B</bold>) with and without EPSTI1 (green) or KSR1 expression (orange) (n = 4; ns, non-significant, statistical analysis using t test with individual variances computed comparing KSR1 knockout versus control (a), KSR1 re-expression (b), and EPSTI1 re-expression (c, d); a, b, c = p &lt; 0.0001; d = p &lt; 0.005). (<bold>C</bold>) Western blot analysis of KSR1 and EPSTI1 in control, KSR1-targeted (KSR1 CRISPR) HCT116 and SW480 cells with and without EPSTI1 or KSR1 expression. HCT116 (<bold>D</bold>) and SW480 (<bold>E</bold>) were transfected with EPSTI1 siRNA (siEPSTI1) or non-targeting control (siControl). After plating cells evenly, cells were counted on day 1, 3, 5, and 7. (n = 4; ns, non-significant **, p &lt; 0.005; ****, p &lt; 0.0001). (<bold>F</bold>) Validation of EPSTI1 knockdown after 7 days was done using western blot.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-66608-fig6-figsupp1-v3.tif"/></fig></fig-group></sec><sec id="s2-7"><title>EPSTI1 re-expression reverses the KSR1-dependent growth inhibition and N-cadherin gene expression</title><p>Knockdown of EPSTI1 in HCT116 and SW480, decreased N-cadherin mRNA expression 50 % (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). Upon KSR1 depletion, N-cadherin mRNA decreased 32 % in HCT116% and 89% in SW480 cells (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). Ectopic expression of EPSTI1 in these cells restored the N-cadherin mRNA expression to levels observed in control SW480 cells, while in HCT116 KSR1 KO, forced EPSTI1 expression increased N-cadherin mRNA levels threefold above that seen in control HCT116 cells (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). We tested the effect of ectopic expression of EPSTI1 on invasion in non-transformed HCECs. We stably expressed MSCV-IRES-GFP or MSCV-IRES-EPSTI1-GFP in HCECs and subjected the cells to Transwell invasion assay through Matrigel (<xref ref-type="fig" rid="fig7">Figure 7B</xref>, top), and observed that EPSTI1 alone was sufficient to dramatically induce the expression of N-cadherin and double the invasive activity of HCECs (<xref ref-type="fig" rid="fig7">Figure 7B</xref>). These data indicate that EPSTI1 mediates the expression of N-cadherin to promote invasive behavior in non-transformed colon epithelial cells and colon cancer cells.</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>EPSTI1 expression in KSR1 KO CRC cells and HCEC cells induces N-cadherin expression and restores anchorage-independent growth in CRC cells.</title><p>(<bold>A</bold>) RT-qPCR analysis of EPSTI1 mRNA (left) and N- cadherin (right) in HCT116 and SW480 cells following KSR1 disruption with and without expression of EPSTI1 (FLAG-EPSTI1) in KSR1 KO cells. (n = 3), **, p &lt; 0.01***, p &lt; 0.001 (<bold>B</bold>) (Top panels) Wild-type (WT) HCEC, HCECs transfected with MSCV-IRES-GFP (IRES-GFP) or MSCV-FLAG-EPSTI1-IRES-GFP (EPSTI1-GFP) were subjected to Transwell migration assay through Matrigel . The number of invaded cells per field were counted, (n = 4); ***, p &lt; 0.001. Representative microscopic images of the respective cells following invasion through Matrigel are shown. (Bottom panels) Western blot analysis of EPSTI1 and N-cadherin from the cell lysates prepared from Wild-type (WT) HCEC, HCECs transfected with MSCV-IRES-GFP (IRES-GFP) or MSCV-FLAG-EPSTI1-IRES-GFP (EPSTI1-GFP). (<bold>C</bold>) KSR1 KO HCT116 and HCT15 cell viability (CellTiter-Glo) on poly-(HEMA)-coated plates at the indicated days with or without EPSTI1 (KSR1 CRISPR + EPSTI1) expression. The data are shown as relative luminescence units mean ± SD, (n = 6); ****, p &lt; 0.0001. The data were analyzed for statistical significance by one-way ANOVA followed by t-test. (<bold>D</bold>) Quantification of anchorage-independent colonies formed by KSR1 knockout HCT116 and SW480 cells with and without EPSTI1 expression (KSR1 CRISPR+ FLAG-EPSTI1) after plating in soft agar. Representative photomicrographs of colonies from each cell line are shown. The data are illustrated as the number of colonies present after 2 weeks, (n = 6) mean ± SD. ****, p &lt; 0.0001. Data were analyzed for statistical significance one-way ANOVA followed by t-test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-66608-fig7-v3.tif"/></fig><p>The E- to N-cadherin switch promotes cancer cell survival following the loss of cell adhesion to the extracellular matrix (<xref ref-type="bibr" rid="bib9">Derksen et al., 2006</xref>; <xref ref-type="bibr" rid="bib48">Onder et al., 2008</xref>). KSR1 also promotes CRC cell survival when detached from a solid substrate (<xref ref-type="bibr" rid="bib15">Fisher et al., 2015</xref>; <xref ref-type="bibr" rid="bib34">McCall et al., 2016</xref>). To determine the extent to which EPSTI1 expression was sufficient to restore CRC cell viability in the absence of KSR1, we grew cells under anchorage-independent conditions either on Poly-(HEMA) (<xref ref-type="fig" rid="fig7">Figure 7C</xref>) or on soft agar (<xref ref-type="fig" rid="fig7">Figure 7D</xref>) following forced expression of EPSTI1 in HCT116, HCT15, and SW480 cells lacking KSR1. Anchorage-independent viability was measured over three days on poly-(HEMA) coated plates. Compared to control HCT116 and HCT15 cells, viability decreased approximately 75 % in cells lacking KSR1. Ectopic expression of EPSTI1 restored viability to approximately 50 % of control levels in both cell lines (<xref ref-type="fig" rid="fig7">Figure 7C</xref>). Similar to our previous findings (<xref ref-type="bibr" rid="bib15">Fisher et al., 2015</xref>; <xref ref-type="bibr" rid="bib25">Kortum et al., 2006</xref>), KSR1 disruption hampered the ability of Ras transformed cells to form colonies on soft agar, the number of colonies formed in HCT116 and SW480 cells dramatically decreased by 75 % in the absence of KSR1. Forced expression of EPSTI1 was sufficient to reverse the suppression of colony formation caused by KSR1 disruption to levels observed in control HCT116 and SW480 cells (<xref ref-type="fig" rid="fig7">Figure 7D</xref>). These results show that despite the absence of KSR1 to maintain and support cell growth, ectopic EPSTI1 expression was able to maintain anchorage-independent viability in CRC cells.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Persistent oncogenic reprogramming of transcription and translation during EMT grants migratory and invasive properties to tumor cells (<xref ref-type="bibr" rid="bib12">Dongre and Weinberg, 2019</xref>; <xref ref-type="bibr" rid="bib44">Nieto et al., 2016</xref>). Multiple studies have established a relationship between oncogenic Ras-mediated ERK signaling and EMT, either through Ras or its downstream effector signaling pathways activating EMT-TFs (<xref ref-type="bibr" rid="bib63">Shin et al., 2010</xref>; <xref ref-type="bibr" rid="bib2">Andreolas et al., 2008</xref>; <xref ref-type="bibr" rid="bib28">Liu et al., 2014</xref>; <xref ref-type="bibr" rid="bib77">Wong et al., 2013</xref>; <xref ref-type="bibr" rid="bib75">Wang et al., 2010</xref>; <xref ref-type="bibr" rid="bib26">Lemieux et al., 2009</xref>; <xref ref-type="bibr" rid="bib10">Diesch et al., 2014</xref>). Silencing of Erbin, a tumor suppresser known to disrupt KSR1-RAF1 interaction, promoted cell migration and invasion of colon cancer cells, but did not identify the mechanism on how KSR1-dependent MAPK signaling affected EMT (<xref ref-type="bibr" rid="bib65">Stevens et al., 2018</xref>). Mediators of EMT- like phenotype activate cap-dependent translation initiation have been associated with increased aggressiveness and metastases of cancer cells, and we have shown that KSR1 can affect translation initiation (<xref ref-type="bibr" rid="bib34">McCall et al., 2016</xref>; <xref ref-type="bibr" rid="bib19">Jechlinger et al., 2003</xref>; <xref ref-type="bibr" rid="bib74">Waerner et al., 2006</xref>; <xref ref-type="bibr" rid="bib53">Prakash et al., 2019</xref>).</p><p>Our observations establish the novel role of the scaffold protein KSR1 promoting the preferential translation of an EMT-related gene, <italic>EPSTI1</italic>, and outline a mechanism for KSR1-dependent stimulation of phenotypic plasticity. Using gene-expression analysis of the polysome-bound mRNA, we discovered KSR1 and ERK increase the translational efficiency of <italic>EPSTI1</italic> mRNA. EPSTI1 mediates KSR1-dependent motility, invasion, and anchorage-independent growth coincident with its suppression of EMT-TF, Slug, elevating E-cadherin expression. EPSTI1 knockdown also decreased the expression of N-cadherin mRNA and protein. In the absence of KSR1, ectopic expression of EPSTI1 was sufficient to suppress E-cadherin expression, stimulate N-cadherin expression and enhance motility and invasive behavior, this invasive behavior was also induced in non-transformed colon cells. These data demonstrate that a KSR1- and ERK-regulated component is critical to the execution of the transcriptional program that drives interconversion between epithelial and mesenchymal phenotypes. These studies of post-transcriptional regulation and mRNA translation reveal the importance of expanding beyond gene expression analysis for detecting mechanisms underlying epithelial plasticity and tumorigenicity.</p><p>The association of EPSTI1 with tumor metastatic potential is supported by observations that <italic>EPSTI1</italic> is highly upregulated in invasive breast cancer tissues and suggested the role of EPSTI1 in promoting metastasis, tumorsphere formation, and stemness (<xref ref-type="bibr" rid="bib41">Nielsen et al., 2002</xref>; <xref ref-type="bibr" rid="bib27">Li et al., 2014</xref>; <xref ref-type="bibr" rid="bib8">de Neergaard et al., 2010</xref>). Although the aberrant expression of EPSTI1 in breast cancer cells is well-established, there is little indication in the literature on the role of EPSTI1 to induce EMT, cancer invasion, and metastasis. The association of EPSTI1 induction of invasion in breast cancer cells was attributed to the increased expression of <italic>Slug</italic> and <italic>Twist</italic> mRNA and increased expression of fibronectin and α2β1 integrins (<xref ref-type="bibr" rid="bib8">de Neergaard et al., 2010</xref>). Another study suggested the interaction of EPSTI1 with valosin-containing protein (VCP) and the subsequent activation of NF-κB signaling contributed to the increased tumor invasion and metastasis (<xref ref-type="bibr" rid="bib27">Li et al., 2014</xref>). Future studies should evaluate the potential of EPSTI1 to directly affect N-cadherin and EMT-TF expression, assess the role of NF-κB signaling in EPSTI1-dependent CRC cell EMT and evaluate the potential of EPSTI1 to contribute to invasion and metastasis in vivo.</p><p>Determining how KSR1- and ERK-dependent signaling promotes EPSTI1 translation should yield novel mechanisms underlying tumor cell metastatic behavior. We show that EPSTI1 mRNA is unchanged upon KSR1 disruption or ERK inhibition (<xref ref-type="fig" rid="fig1">Figures 1E</xref> and <xref ref-type="fig" rid="fig2">2D</xref>) and KSR1 does not contribute to UPS-mediated protein degradation (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2E</xref>), suggesting that KSR1 regulates EPSTI1 through post-transcriptional modifications enhancing its preferential loading onto the polysomes. Differential mRNA splicing is implicated in EMT-related processes and splicing regulatory factors have been implicated in the motility and invasive behavior of tumor cells (<xref ref-type="bibr" rid="bib49">Park et al., 2019</xref>; <xref ref-type="bibr" rid="bib52">Pradella et al., 2017</xref>). One possibility is that KSR1 signaling promotes the splicing of EPSTI1 that promotes it’s the preferential translational contributing to increased motility and invasion.</p><p>Upon removal of KSR1 or EPSTI1, the tumor cells switch back from highly migratory and invasive EMT-like state to the epithelial state. However, the invasive property is not completely lost in KSR1/EPSTI1 disruption (<xref ref-type="fig" rid="fig4">Figure 4B</xref>), which could be attributed to other mesenchymal markers retained in the cells, such as vimentin (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>). Investigating other EMT-related mRNAs that are preferentially translated in response to KSR1-scaffolded ERK signaling may reveal additional mRNAs that make previously unappreciated contributions to cell migration, invasion, and EMT. Constitutive KSR1 or EPSTI1 knockout yields developmentally normal mice (<xref ref-type="bibr" rid="bib32">Lozano et al., 2003</xref>; <xref ref-type="bibr" rid="bib40">Nguyen et al., 2002</xref>; <xref ref-type="bibr" rid="bib22">Kim et al., 2018</xref>). While KSR1 or EPSTI1 may not be essential to EMT during normal development, they may play a role in other EMT-dependent events such as wound healing where cells collectively migrate, differentiate, and re-epithelialize keratinocytes around and/or within the damaged site. If their role in EMT is exclusive to tumor cells it will reveal a key vulnerability for therapeutic evaluation. Further characterization of KSR1, EPSTI1 and the additional effectors repurposed by dysregulated translation in CRC should reveal additional novel mechanisms critical to CRC tumor survival and progression.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">Colorectal carcinoma, epithelial</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">HCT116 (ATCC, Cat# CCL-247, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0291">CVCL_0291</ext-link>)</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">Colorectal carcinoma, epithelial</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">HCT15 (ATCC, Cat# CCL-225, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0292">CVCL_0292</ext-link>)</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">Colorectal adenocarcinoma, epithelial</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">SW480 (ATCC, Cat# CCL-228, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0546">CVCL_0546</ext-link>)</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">Immortalized colon epithelial</td><td align="left" valign="bottom">Obtained from Dr. Jerry Shay</td><td align="left" valign="bottom">HCEC</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">Kidney; epithelial fibroblast (fetus)</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">HEK-293T (ATCC Cat# CRL-3216, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0063">CVCL_0063</ext-link>)</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">Kidney; epithelial fibroblast (fetus)</td><td align="left" valign="bottom">Obtained from Rob Kortum</td><td align="left" valign="bottom">Phoenix-GP</td><td align="left" valign="bottom">Available at ATCC (Cat# CRL-321)</td></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">siRNA to non-targeting control</td><td align="left" valign="bottom">Dharmacon</td><td align="left" valign="bottom">Cat# D-001810-01-20</td><td align="left" valign="bottom">UGGUUUACAUGUCGACUAA</td></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">siRNA to EPSTI1</td><td align="left" valign="bottom">Dharmacon</td><td align="left" valign="bottom">Cat# 015094-09-0020</td><td align="left" valign="bottom">GAACAGAGCUAAACCGGUU</td></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">siRNA to EPSTI1</td><td align="left" valign="bottom">Dharmacon</td><td align="left" valign="bottom">Cat# 015094-12-0020</td><td align="left" valign="bottom">UCUGGAGGCUGUUGGAAUA</td></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">Con shRNA#1</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib15">Fisher et al., 2015</xref></td><td align="left" valign="bottom">pLKO.1 MC1 puro</td><td align="left" valign="bottom">CAACAAGATGAAGAGCACCAA</td></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">KSR1 shRNA#1</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib15">Fisher et al., 2015</xref></td><td align="left" valign="bottom">pLKO.1 KSR.1 puro</td><td align="left" valign="bottom">GTGCCAGAAGAGCATGATTTT</td></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">KSR1 shRNA#2</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib15">Fisher et al., 2015</xref></td><td align="left" valign="bottom">pLKO.1 KSR.2 puro</td><td align="left" valign="bottom">GCTGTTCAAGAAAGAGGTGAT</td></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">CON sgRNA#1</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">pCAG-SpCas9-GFP-U6-gNC1</td><td align="left" valign="bottom">GTATTACTGATATTGGTGGG</td></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">KSR1 sgRNA#1</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">pCAG-SpCas9-GFP-U6-gCR1.1</td><td align="left" valign="bottom">TTGGATGCGCGGCGGGAAAG</td></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">KSR1 sgRNA#2</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">pCAG-SpCas9-GFP-U6-gCR1.2</td><td align="left" valign="bottom">CTGACACGGAGATGGAGCGT</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">FLAG-KSR1 (plasmid)</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib15">Fisher et al., 2015</xref></td><td align="left" valign="bottom">MSCV-KSR1-IRES-GFP</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">FLAG-EPSTI1 (plasmid)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">MSCV-FLAG-EPSTI1-IRES-GFP</td><td align="left" valign="bottom">MGC Human EPSTI1 Sequence-Verified cDNA (Cat# MHS6278-202832484) cloned into MSCV-IRES-GFP construct</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">N-cad OE (plasmid)</td><td align="left" valign="bottom"><italic>Gift from Dr. Keith Johnson</italic></td><td align="left" valign="bottom">N-cadherin-mGFP</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">EPSTI1 (PCR primer)</td><td align="left" valign="bottom">IDT</td><td align="left" valign="bottom">Cat# Hs.PT.58.50471678</td><td align="left" valign="bottom">Forward primer 5’-GTGAATTACTGGAACTGAAACGG-3’<break/>Reverse primer 5’ TCCAACAGCCTCCAGATTG 3’ Tm 55 °C, Exon Location 10–11</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">N-cadherin (PCR primer)</td><td align="left" valign="bottom">IDT</td><td align="left" valign="bottom">Cat# Hs.PT.58.26024443</td><td align="left" valign="bottom">Forward primer 5’-GTTTGCCAGTGTGACTCCA-3’<break/>Reverse primer 5’-CATACCACAAACATCAGCACAAG-3’<break/>Tm 55 °C, Exon Location 13–14</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">HPRT1 (PCR primer)</td><td align="left" valign="bottom">IDT</td><td align="left" valign="bottom">Cat# Hs.PT.58v.45621572</td><td align="left" valign="bottom">Forward Primer: 5’ GTATTCATTATAGTCAAGGGCATATCC 3’<break/>Reverse Primer: 5’AGATGGTCAAGGTCGCAAG 3’<break/>Tm 60 °C, Exon Location 8–9</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">ZEB1 (PCR primer)</td><td align="left" valign="bottom">IDT</td><td align="left" valign="bottom">Cat# Hs.PT.58.39178574</td><td align="left" valign="bottom">Forward primer 5’-GAGGAGCAGTGAAAGAGAAGG-3’<break/>Reverse primer 5’-TACTGTACATCCTGCTTCATCTG-3’<break/>Tm 60 °C, Exon Location 3–5</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">SLUG (PCR primer)</td><td align="left" valign="bottom">IDT</td><td align="left" valign="bottom">Cat# Hs.PT.58.50471678</td><td align="left" valign="bottom">Forward primer 5’-AGGACACATTAGAACTCACACG-3’<break/>Reverse primer 5’-CAGATGAGCCCTCAGATTTGAC-3’<break/>Tm 55 °C, Exon Location 2–3</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-KSR1, Rabbit polyclonal</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat# ab68483</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-EPSTI1, Rabbit polyclonal</td><td align="left" valign="bottom">Proteintech</td><td align="left" valign="bottom">Cat# 11627–1-AP, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2877786">AB_2877786</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom" rowspan="2">Antibody</td><td align="left" valign="bottom" rowspan="2">Anti-N-cadherin</td><td align="left" valign="bottom"><italic>Gift from Dr. Keith Johnson</italic></td><td align="left" valign="bottom">Cat# 13A9</td><td align="left" valign="bottom">WB (1:20)</td></tr><tr><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat# 13116, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2687616">AB_2687616</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom" rowspan="2">Antibody</td><td align="left" valign="bottom" rowspan="2">Anti-E-cadherin</td><td align="left" valign="bottom"><italic>Gift from Dr. Keith Johnson</italic></td><td align="left" valign="bottom">Cat# <italic>4A2</italic></td><td align="left" valign="bottom">WB (1:10) IF (1:1)</td></tr><tr><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat# 3195, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2291471">AB_2291471</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Slug, Rabbit monoclonal</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat# 9585, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2239535">AB_2239535</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Lamin β2, Rabbit monoclonal</td><td align="left" valign="bottom">Abclonal</td><td align="left" valign="bottom">Cat# A6483, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2767083">AB_2767083</ext-link></td><td align="left" valign="bottom">WB (1:2000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-β actin, Mouse monoclonal</td><td align="left" valign="bottom">Santa Cruz</td><td align="left" valign="bottom">Cat# 47778, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2714189">AB_2714189</ext-link></td><td align="left" valign="bottom">WB (1:2000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-phospho RSK S380, Rabbit polyclonal</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat# 9341, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_330753">AB_330753</ext-link></td><td align="left" valign="bottom">WB (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Total RSK, Rabbit monoclonal</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat# 9355, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_659900">AB_659900</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-phospho p70S6K T389, Rabbit polyclonal</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat# 9206, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2285392">AB_2285392</ext-link></td><td align="left" valign="bottom">WB (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-total p70S6K, Rabbit polyclonal</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat# 9202, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_331676">AB_331676</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-SNAIL, Rabbit monoclonal</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat# 3879, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2255011">AB_2255011</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Vimentin, Rabbit monoclonal</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat# 5741, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10695459">AB_10695459</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Cell culture</title><p>Colorectal cancer cell lines HCT116, HCT15, and SW480 were acquired from American Type Culture Collection (ATCC). The cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) containing high glucose with 10 % fetal bovine serum (FBS) and grown at 37 °C with ambient O<sub>2</sub> and 5 % CO<sub>2</sub>. Cells were routinely tested for mycoplasma. No further authentication of cell lines was performed by the authors. Non-transformed immortalized human colon epithelial cell line (HCEC) was a gift from J. Shay (University of Texas [UT] Southwestern) and were grown and maintained as described previously (<xref ref-type="bibr" rid="bib15">Fisher et al., 2015</xref>; <xref ref-type="bibr" rid="bib55">Roig et al., 2010</xref>). HCECs were grown in a hypoxia chamber with 2% O<sub>2</sub> and 5% CO<sub>2</sub> at 37°C in four parts DMEM to 1 part medium 199 (Sigma-Aldrich #M4530) with 2% cosmic calf serum (GE Healthcare, #SH30087.03), 25 ng/mL EGF (R&amp;D, Minneapolis, MN #236-EG), 1 µg/mL hydrocortisone (Sigma-Aldrich, #H0888), 10 µg/mL insulin (Sigma-Aldrich, #I550), 2 µg/mL transferrin (Sigma-Aldrich, #T1428), 5 nM sodium selenite (Sigma-Aldrich #S5261), and 50 µg/mL gentamicin sulfate (Gibco #15750–060) as described previously (<xref ref-type="bibr" rid="bib15">Fisher et al., 2015</xref>). Normal and quadruple mutant AKPS (APC <sup>KO</sup>/KRAS<sup>G12D</sup>/P53 <sup>KO</sup>/SMAD4<sup>KO</sup>) tumor colon organoids obtained from the Living Organoid Biobank housed by Dr. Hans Clevers and cultured as described previously (<xref ref-type="bibr" rid="bib13">Drost et al., 2015</xref>; <xref ref-type="bibr" rid="bib73">van de Wetering et al., 2015</xref>). The normal organoids were cultured in medium containing advanced DMEM/F12 (Invitrogen #12634) with 50 % WNT conditioned media (produced using stably transfected L cells), 20 % R-spondin1, 10 % Noggin, 1 X B27 (Invitrogen #17504–044), 10 mM nicotinamide (Sigma-Aldrich #N0636), 1.25 mM N-acetylcysteine (Sigma-Aldrich #A9165-5G), 50 ng/mL EGF (Invitrogen #PMG8043), 5000 nM TGF-b type I receptor inhibitor A83-01 (Tocris #2939), 10 nM Prostaglandin E2 (Tocris #2296), 3 µM p38 inhibitor SB202190 (Sigma-Aldrich #S7067), and 100 µg/mL Primocin (Invivogen #ant-pm-1). The quadruple mutant AKPS organoids were grown in media lacking WNT conditioned media, R-spondin 1, noggin and EGF and containing 10 µM nutlin-3 (Sigma #675576-98-4).</p></sec><sec id="s4-2"><title>RNA interference</title><p>Approximately 500,000 cells were transfected using a final concentration of 20 nM EPSTI1 (J-015094-09-0020 and J-015094-12-0020) or non-targeting (D-001810-01-20 and D-001810-02-20) ON-TARGETplus siRNAs from GE Healthcare Dharmacon using 20 µL of Lipofectamine RNAiMAX (ThermoFisher #13778–150) and 500 µL OptiMEM (ThermoFisher #31985070). Cells were incubated for 72 hr before further analysis.</p></sec><sec id="s4-3"><title>Generation of KSR1 shRNA knockdown and KSR1 CRISPR/Cas9 knockout cell lines</title><p>A lentiviral pLKO.1-puro constructs targeting KSR1, and non-targeting control were transfected into HEK-293T cells using trans-lentiviral packaging system (ThermoFisher Scientific). The virus was collected, and the medium was replaced 48 hr post transfection. HCT116 and HCT15 cells were infected with virus with 8 µg/mL of Polybrene for several days. The population of cells with depleted KSR1 was selected with 10 µg/mL puromycin. The KSR1 knockdown was confirmed via western blotting.</p><p>pCAG-SpCas9-GFP-U6-gRNA was a gift from Jizhong Zou (Addgene plasmid #79144), KSR1 sgRNA and non-targeting control sgRNA was cloned into the pCas9 vector. Both the non-targeting control and sgKSR1 were transfected into HCT116, HCT15, and SW480 cells using PEI transfection as described previously (<xref ref-type="bibr" rid="bib31">Longo et al., 2013</xref>). The GFP-positive cells were sorted 48 hr post transfection, and colonies were picked by placing sterile glass rings around individual colonies.</p><p>MSCV-IRES-GFP, MSCV-IRES-KSR1-GFP, MSCV-IRES-FLAG-EPSTI1, and N-cadherin mGFP constructs were transfected into Phoenix GP cells using trans-lentiviral packaging system (ThermoFisher Scientific). The virus was collected, and the medium was replaced 48 hours post transfection. HCECs/ KSR1-CRISPR HCT116, HCT15, and SW480 cells were infected with virus with 8 µg/mL of Polybrene for 96 hours. The population of cells with KSR1 expression was selected following GFP sorting using fluorescence-activated cell sorting (FACS). The KSR1/EPSTI1 expression was confirmed via western blotting.</p></sec><sec id="s4-4"><title>Cell lysis and western blot analysis</title><p>Whole cell lysate was extracted in radioimmunoprecipitation assay (RIPA) buffer containing 50 mM Tris-HCl, 1% NP-40, 0.5 % Na deoxycholate, 0.1 % Na dodecyl sulfate, 150 mM NaCl, 2 mM EDTA, 2 mM EGTA, and 1 X protease and phosphatase inhibitor cocktail (Halt, ThermoFisher Scientific #78440). Cytoplasmic and nuclear fractionation was performed using NE-PER Nuclear and Cytoplasmic Extraction Reagents (ThermoFisher Scientific #PI78835). The estimation of protein concentration was done using BCA protein assay (Promega #PI-23222, PI-23224). Samples were diluted using 1 X sample buffer (4 X stock, LI-COR #928–40004) with 100 mM dithiothreitol (DTT) (10 X stock, 1 mM, Sigma #D9779-5G). The protein was separated using 8–12% SDS-PAGE and transferred to nitrocellulose membrane. The membrane was blocked with Odyssey TBS blocking buffer (LICOR-Biosciences #927–50003) for 45 min at room temperature, then incubated with primary antibodies (<italic>Key Resources Table</italic>) at least overnight at 4°C. IRDye 800CW and 680RD secondary antibodies (LI-COR Biosciences # 926–32211, # 926–68072) were diluted 1:10,000 in 0.1% TBS-Tween and imaged on the Odyssey Classic Scanner (LI-COR Biosciences).</p></sec><sec id="s4-5"><title>Polysome profiling</title><p>Cells were treated with 100 µg/mL cycloheximide (Sigma #C4859) on ice in PBS for 10 min. The cells were lysed with 10 mM HEPES, 100 mM KCL, 5 mM MgCl<sub>2</sub>, 100 µg/mL cycloheximide, 2 mM DTT, 1 % Triton-X100, 2.5 µl RNaseOUT (ThermoFisher Scientific #10777019). The lysates were cleared by centrifugation for 10 min at 13,200 rpm at 4°C. Approximately 200 µL of the total RNA was collected in a new RNAse-free microcentrifuge tube and the remaining supernatant was loaded onto a 15–45% sucrose gradient. The samples were spun at 37,500 rpm for 2 hr at 4°C in SW55Ti Beckman ultracentrifuge and separated on a gradient fractionation system to resolve the polysomes. Polysome profiles were identified at 260 nM using an absorbance detector. Gradient fractions were collected dropwise at 0.75 mL/min. For RNAseq, the total RNA and RNA pooled from the polysome fraction (fractions 6–9) of three sets of independently isolated cells was isolated using RNAzol (Molecular Research Centre #RN 190) according to the manufacture’s protocol. RNA purity was evaluated by the UNMC DNA Sequencing Core using a BioAnalyzer.</p></sec><sec id="s4-6"><title>RNA-sequencing and analysis</title><p>RNA sequencing (RNA seq) was conducted by the UNMC DNA Sequencing Core. For RNA-seq, RNA was purified from three biological replicates of total and polysome-bound RNA from HCT116 and HCT15, control and KSR1 knockdown cells as previously described. Stranded RNA sequencing libraries were prepared as per manufactures’ protocol using TrueSeq mRNA protocol kit (Illumina) and 500 ng of the total RNA was used for each of the samples. Purified libraries were pooled at a 0.9 pM concentration and sequenced on an Illumina NextSeq550 instrument, using a 75 SR High-output flow cell, to obtain approximately 45 million single-end reads per sample. NGS short reads from RNA-seq experiments was downloaded from the HiSeq2500 server in FASTQ format. FastQC (<ext-link ext-link-type="uri" xlink:href="http://www.bioinformatics.babraham.ac.uk/projects/fastqc/">http://www.bioinformatics.babraham.ac.uk/projects/fastqc/</ext-link>) was used to perform quality control checks on the <italic>fastq</italic> files that contain the raw short reads from sequencing. The reads were then mapped to the <italic>Homo sapiens</italic> (human) reference genome assembly GRCh38 (hg38) using STAR v2.7 alignment. The <monospace>--quantMode GeneCounts</monospace> option in STAR 2.7 (<xref ref-type="bibr" rid="bib11">Dobin et al., 2013</xref>) was used to obtain the HTSeq counts per gene. Gencode v32 Gene Transfer Format (GTF) was used for the transcript/gene annotations. The output files were combined into a matrix using R. The gene counts were further used as input for downstream analysis using Anota2seq. The high-throughput sequencing data have been deposited in the Gene Expression Omnibus (GEO) database, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo">http://www.ncbi.nlm.nih.gov/geo</ext-link> (accession no. GSE164492).</p></sec><sec id="s4-7"><title>Translational efficiency</title><p>The altered levels of total mRNA can impact the changes in the pool of polysome-bound mRNA, leading to a spurious calculation translational efficiency (TE). Anota2seq (<xref ref-type="bibr" rid="bib46">Oertlin et al., 2019</xref>) allows the quantification of actual changes in TE. TE was calculated using the R Bioconductor anota2Seq package for the HTSeq counts by first removing genes that did not contain expression values in more than 10% of the samples. 16,023 genes remained after this step. TMM normalization was further performed prior to log2 counts per million computation (CPM) using the voom function of the limma package using the anota2seqDataSetFromMatrix function (with parameters datatype = “RNAseq”, normalize = TRUE, transformation = “TMM-log2”). TE was calculated using the 2 × 2 factorial design model for the two cell lines (HCT116 and HCT15). Genes were considered significantly regulated at Adjusted p-value &lt; 0.05 when passing filtering criteria (parameters for anota2seqSelSigGenes function) using Random variance Model [useRVM = TRUE], [selDeltaPT &gt; log2(1.2)], [minSlopeTranslation &gt;−1], [maxSlopeTranslation &lt;2], [selDeltaTP&gt; log2(1.2)], [minSlopeBuffering &gt;−2] and [maxSlopeBuffering &lt;1], [selDeltaP&gt; log2 (1)], [selDetaT &gt; log2 (1)]. The scatterplots were obtained using the anota2seqPlotFC function. The heatmaps were generated using the TE values for the two cell lines using the R Bioconductor ComplexHeatmap package.</p></sec><sec id="s4-8"><title>Anchorage-independent growth [poly-(HEMA)] assay</title><p>Poly-(HEMA) stock solution (10 mg/mL) was prepared by dissolving poly-(HEMA) (Sigma #3932–25 G) in 95% ethanol at 37°C until fully dissolved (overnight). Ninety-six-well optical bottom plates (Thermo Scientific Nunc #165305) were coated in 200 µL of poly-(HEMA) solution and allowing it to evaporate. Cells were plated in complete growth medium of the poly-(HEMA) coated plates at a concentration of 10,000 cells/ 100 µL. Cell viability was measured at the indicated time points by the addition of CellTiter-Glo 2.0 reagent (Promega #G9242) and luminescence was measured (POLARstar Optima plate reader) according to the manufacturer’s protocol.</p></sec><sec id="s4-9"><title>Anchorage-independent growth (soft agar) assay</title><p>A total of 6000 cells were seeded in 1.6 % NuSieve Agarose (Lonza #50081) to assess anchorage-independent growth according to the protocol of <xref ref-type="bibr" rid="bib15">Fisher et al., 2015</xref>. Colonies greater than 100 µm in diameter from six replicates per sample were counted, representative photomicrographs were taken after 10–14 days of incubation at 37°C and 5 % CO2.</p></sec><sec id="s4-10"><title>RT-qPCR</title><p>Cells were harvested using 1 mL TRIzol (ThermoFisher Scientific #15596026) and RNA extraction was performed using RNeasy spin columns (Qiagen #74104). RNA was eluted with nuclease-free water. The RNA was quantified using a NanoDrop 2000 (Thermo Scientific) and Reverse Transcription (RT) was performed with 2 µg RNA per 40 µl reaction mixture using iScript Reverse Transcription Supermix (Bio-Rad #170–8891). RT-qPCR was performed using primers antibodies (<italic>Key Resources Table</italic>), and all targets were amplified using SsoAdvanced Universal SYBR green Supermix (Bio-Rad #1725271) with 40 cycles on a QuantStudio 3 (ThermoFisher Scientific). The analysis was performed using 2<sup>-ΔΔC</sup><sub>T</sub> method (<xref ref-type="bibr" rid="bib60">Schmittgen and Livak, 2008</xref>). For polysome gradients, the RNA levels were quantified from the cDNA using the standard curve method, summed across all fractions (<xref ref-type="bibr" rid="bib24">Kortum and Lewis, 2004</xref>; <xref ref-type="bibr" rid="bib40">Nguyen et al., 2002</xref>; <xref ref-type="bibr" rid="bib14">Fisher et al., 2011</xref>; <xref ref-type="bibr" rid="bib15">Fisher et al., 2015</xref>; <xref ref-type="bibr" rid="bib37">Morrison et al., 2009</xref>; <xref ref-type="bibr" rid="bib54">Rao et al., 2020</xref>) and presented as a percentage of the total fractions.</p></sec><sec id="s4-11"><title>Cell migration (scratch-test) assay</title><p>An in vitro scratch test was performed with the IncuCyte Zoom according to the manufacturer’s instructions. Approximately 35,000 cells were seeded onto a 96-well ImageLock plates (Essen BioScience #4379) and grown to 90–95% confluency. The scratches were created using WoundMaker (Essen BioScience #4563) in all the wells, after which the cells were washed with 1 x PBS, and media without containing serum was replaced. Images of the cells were obtained every 20 min for a total duration of 72 hr using IncuCyte Kinetic Live Cell Imaging System (Essen BioScience) and analyzed using the IncuCyte Zoom software (Essen BioScience). IncuCyte Software was used to calculate the relative wound density metric to quantify the cell migration over time. The metric is designed to be zero at t = 0% and 100% when cell density inside the wound is the same as the cell density outside the initial wound, thus, allowing to experimentally quantify the effects of cell migration separate from changes that occurs as result of cell proliferation.</p></sec><sec id="s4-12"><title>Cell invasion (transwell) assay</title><p>Transwell inserts (24-well Millicell cell culture, #MCEP24H48) were coated with 50 µL of Matrigel (Corning, # 356234) and allowed to solidify for 15–30 min. Approximately 20,000 stably generated knockout cells, or cells after 48 hr of transfection were plated in serum free media in the upper chamber of transwell insert. Cells were allowed to invade toward 10% serum containing media in the lower chamber for 24 hr, after which cells and gel in the upper chamber was gently removed with a sterile cotton applicator and the cells in the lower side of the insert was fixed with 3.7% formaldehyde for 2 min, permeabilized with 100% methanol for 20 min and stained with Giemsa for 15 min. The numbers of cells were counted using an inverted microscope at ×20 magnification.</p></sec><sec id="s4-13"><title>Immunofluorescence assay</title><p>Cells were plated on glass coverslips to 70–80% confluence for 48 hr in growth media. Cells were fixed in 1 % formaldehyde diluted in PBS for 15 min. The cells were rinsed three times with PBS for 5 min and coverslips were blocked for 1 hr with 1 X PBS/ 5% goat serum/0.3% Triton X-100 and then incubated with E-cadherin antibody (#4A2) overnight. Cells were washed three times for 5 min with PBS and incubated in anti-mouse IgG Alexa Fluor 555 Conjugate (Cell signaling #4409) at a dilution of 1:500 for 1 hr. Coverslips were rinsed three times for 5 min in PBS and briefly rinsed in distilled water prior to mounting in Prolong Gold Antifade Reagent with DAPI (Cell signaling #8961). All Images were acquired using a Zeiss LSM-780 confocal microscope and processed using ZEISS ZEN 3.2 (blue edition) software.</p></sec><sec id="s4-14"><title>Cell growth assay</title><p>Cells were transfected with siRNA targeting EPSTI1 or a non-targeting control as previously described. The next day, control, KSR1-CRISPR, KSR1-CRISPR HCT116 and SW480 cells expressing KSR1 or EPSTI1, siControl and siEPSTI1 HCT116 and SW480 cells were counted and approximately 1 × 10<sup>4</sup> cells were plated in all wells of a 12-well plate for each condition. The next day, four of the wells from each 12-well plate were harvested and stained with 0.4% trypan blue (Sigma, # T6146-5G) and were then counted and recorded using Countess II automated cell counter (ThermoFisher, #A27977). This procedure was repeated for indicated days and the cells from day 7 were harvested and a western blot analysis was performed to ensure the expression of the target protein was maintained. Cell counts were then graphed in GraphPad.</p></sec><sec id="s4-15"><title>Reagents</title><p>The ERK inhibitor SCH772984 was purchased from SelleckChem (S7101), Z-Leu-Leu-Leu-al (MG132, S2619) were purchased from Fisher and mTOR inhibitor AZD8055 (HY_10422) MedChem Express.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Validation, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Investigation, Methodology, software</p></fn><fn fn-type="con" id="con4"><p>Data curation, Methodology, resources</p></fn><fn fn-type="con" id="con5"><p>Investigation, Methodology, resources</p></fn><fn fn-type="con" id="con6"><p>resources</p></fn><fn fn-type="con" id="con7"><p>resources</p></fn><fn fn-type="con" id="con8"><p>resources</p></fn><fn fn-type="con" id="con9"><p>resources</p></fn><fn fn-type="con" id="con10"><p>resources, Writing – review and editing</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, funding-acquisition, project-administration, resources, supervision, Visualization, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Genes translationally altered by KSR1.</title><p>Translational efficiency of mRNAs (58 decreased; 40 increased) upon KSR1 knockdown in HCT116 and HCT15 cells, related to <xref ref-type="fig" rid="fig1">Figure 1B</xref>.</p></caption><media xlink:href="elife-66608-supp1-v3.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>KSR1-dependent genes predicted in mesenchymal-up signature identified by GSEA.</title><p>GSEA for the subset of translationally controlled genes involved in ‘Hallmark EMT signature’, ‘Jechlinger EMT Up’, and ‘Gotzmann EMT up’ in a KSR1-dependent manner.</p></caption><media xlink:href="elife-66608-supp2-v3.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media xlink:href="elife-66608-transrepform1-v3.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="sdata1"><label>Source data 1.</label><caption><title>Translational efficiency of mRNAs significantly altered by KSR1 analyzed using Anota2seq.</title></caption><media xlink:href="elife-66608-data1-v3.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>The high-throughput sequencing data have been deposited in the Gene Expression Omnibus (GEO) database, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo">http://www.ncbi.nlm.nih.gov/geo</ext-link> (accession no. GSE164492).</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>C</given-names></name><name><surname>Southekal</surname><given-names>S</given-names></name><name><surname>Lewis</surname><given-names>RE</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>Next generation sequencing analysis of control and KSR1 knockdown CRC cell line translatomes</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE164492">GSE164492</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank Dr. Xuan Zhang, and Dr. Kai Fu for their assistance with polysome profiling, Lisa E Humphrey-Brattain for their assistance with the colon organoid culture, the UNMC Advanced Microscopy Core, and the UNMC Cell Analysis Facility. We declare no conflicts of interest. This work was supported by P20 GM121316 (REL), and the Fred &amp; Pamela Buffett Cancer Center Support Grant (P30 CA036727). The funders had no role in the study design, data collection and interpretation, or the decision to submit the work for publication.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aiello</surname><given-names>NM</given-names></name><name><surname>Maddipati</surname><given-names>R</given-names></name><name><surname>Norgard</surname><given-names>RJ</given-names></name><name><surname>Balli</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Yuan</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>EMT Subtype Influences Epithelial Plasticity and Mode of Cell Migration</article-title><source>Developmental Cell</source><volume>45</volume><fpage>681</fpage><lpage>695</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2018.05.027</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andreolas</surname><given-names>C</given-names></name><name><surname>Kalogeropoulou</surname><given-names>M</given-names></name><name><surname>Voulgari</surname><given-names>A</given-names></name><name><surname>Pintzas</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Fra-1 regulates vimentin during Ha-RAS-induced epithelial mesenchymal transition in human colon carcinoma cells</article-title><source>International Journal of Cancer</source><volume>122</volume><fpage>1745</fpage><lpage>1756</lpage><pub-id pub-id-type="doi">10.1002/ijc.23309</pub-id><pub-id pub-id-type="pmid">18098284</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Araki</surname><given-names>K</given-names></name><name><surname>Shimura</surname><given-names>T</given-names></name><name><surname>Suzuki</surname><given-names>H</given-names></name><name><surname>Tsutsumi</surname><given-names>S</given-names></name><name><surname>Wada</surname><given-names>W</given-names></name><name><surname>Yajima</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>E/N-cadherin switch mediates cancer progression via TGF-beta-induced epithelial-to-mesenchymal transition in extrahepatic cholangiocarcinoma</article-title><source>British Journal of Cancer</source><volume>105</volume><fpage>1885</fpage><lpage>1893</lpage><pub-id pub-id-type="doi">10.1038/bjc.2011.452</pub-id><pub-id pub-id-type="pmid">22068819</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avdulov</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Michalek</surname><given-names>V</given-names></name><name><surname>Burrichter</surname><given-names>D</given-names></name><name><surname>Peterson</surname><given-names>M</given-names></name><name><surname>Perlman</surname><given-names>DM</given-names></name><name><surname>Manivel</surname><given-names>JC</given-names></name><name><surname>Sonenberg</surname><given-names>N</given-names></name><name><surname>Yee</surname><given-names>D</given-names></name><name><surname>Bitterman</surname><given-names>PB</given-names></name><name><surname>Polunovsky</surname><given-names>VA</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Activation of translation complex EIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells</article-title><source>Cancer Cell</source><volume>5</volume><fpage>553</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2004.05.024</pub-id><pub-id pub-id-type="pmid">15193258</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brandt</surname><given-names>R</given-names></name><name><surname>Sell</surname><given-names>T</given-names></name><name><surname>Lüthen</surname><given-names>M</given-names></name><name><surname>Uhlitz</surname><given-names>F</given-names></name><name><surname>Klinger</surname><given-names>B</given-names></name><name><surname>Riemer</surname><given-names>P</given-names></name><name><surname>Giesecke-Thiel</surname><given-names>C</given-names></name><name><surname>Schulze</surname><given-names>S</given-names></name><name><surname>El-Shimy</surname><given-names>IA</given-names></name><name><surname>Kunkel</surname><given-names>D</given-names></name><name><surname>Fauler</surname><given-names>B</given-names></name><name><surname>Mielke</surname><given-names>T</given-names></name><name><surname>Mages</surname><given-names>N</given-names></name><name><surname>Herrmann</surname><given-names>BG</given-names></name><name><surname>Sers</surname><given-names>C</given-names></name><name><surname>Blüthgen</surname><given-names>N</given-names></name><name><surname>Morkel</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Cell type-dependent differential activation of ERK by oncogenic KRAS in colon cancer and intestinal epithelium</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>2919</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-10954-y</pub-id><pub-id pub-id-type="pmid">31266962</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chresta</surname><given-names>CM</given-names></name><name><surname>Davies</surname><given-names>BR</given-names></name><name><surname>Hickson</surname><given-names>I</given-names></name><name><surname>Harding</surname><given-names>T</given-names></name><name><surname>Cosulich</surname><given-names>S</given-names></name><name><surname>Critchlow</surname><given-names>SE</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity</article-title><source>Cancer Research</source><volume>70</volume><fpage>288</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-1751</pub-id><pub-id pub-id-type="pmid">20028854</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>J</given-names></name><name><surname>Cargnello</surname><given-names>M</given-names></name><name><surname>Topisirovic</surname><given-names>I</given-names></name><name><surname>Pelletier</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Translation Initiation Factors: Reprogramming Protein Synthesis in Cancer</article-title><source>Trends in Cell Biology</source><volume>26</volume><fpage>918</fpage><lpage>933</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2016.06.005</pub-id><pub-id pub-id-type="pmid">27426745</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Neergaard</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Villadsen</surname><given-names>R</given-names></name><name><surname>Fridriksdottir</surname><given-names>AJ</given-names></name><name><surname>Rank</surname><given-names>F</given-names></name><name><surname>Timmermans-Wielenga</surname><given-names>V</given-names></name><name><surname>Langerød</surname><given-names>A</given-names></name><name><surname>Børresen-Dale</surname><given-names>A-L</given-names></name><name><surname>Petersen</surname><given-names>OW</given-names></name><name><surname>Rønnov-Jessen</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Epithelial-stromal Interaction 1 (epsti1) substitutes for peritumoral fibroblasts in the tumor microenvironment</article-title><source>The American Journal of Pathology</source><volume>176</volume><fpage>1229</fpage><lpage>1240</lpage><pub-id pub-id-type="doi">10.2353/ajpath.2010.090648</pub-id><pub-id pub-id-type="pmid">20133812</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Derksen</surname><given-names>PW</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Saridin</surname><given-names>F</given-names></name><name><surname>van der Gulden</surname><given-names>H</given-names></name><name><surname>Zevenhoven</surname><given-names>J</given-names></name><name><surname>Evers</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis</article-title><source>Cancer Cell</source><volume>10</volume><fpage>437</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2006.09.013</pub-id><pub-id pub-id-type="pmid">17097565</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diesch</surname><given-names>J</given-names></name><name><surname>Sanij</surname><given-names>E</given-names></name><name><surname>Gilan</surname><given-names>O</given-names></name><name><surname>Love</surname><given-names>C</given-names></name><name><surname>Tran</surname><given-names>H</given-names></name><name><surname>Fleming</surname><given-names>NI</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Widespread FRA1-dependent control of mesenchymal transdifferentiation programs in colorectal cancer cells</article-title><source>PLOS ONE</source><volume>9</volume><elocation-id>e88950</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0088950</pub-id><pub-id pub-id-type="pmid">24658684</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobin</surname><given-names>A</given-names></name><name><surname>Davis</surname><given-names>CA</given-names></name><name><surname>Schlesinger</surname><given-names>F</given-names></name><name><surname>Drenkow</surname><given-names>J</given-names></name><name><surname>Zaleski</surname><given-names>C</given-names></name><name><surname>Jha</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>STAR: ultrafast universal RNA-seq aligner</article-title><source>Bioinformatics</source><volume>29</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts635</pub-id><pub-id pub-id-type="pmid">23104886</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dongre</surname><given-names>A</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>20</volume><fpage>69</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1038/s41580-018-0080-4</pub-id><pub-id pub-id-type="pmid">30459476</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drost</surname><given-names>J</given-names></name><name><surname>van Jaarsveld</surname><given-names>RH</given-names></name><name><surname>Ponsioen</surname><given-names>B</given-names></name><name><surname>Zimberlin</surname><given-names>C</given-names></name><name><surname>van Boxtel</surname><given-names>R</given-names></name><name><surname>Buijs</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Sequential cancer mutations in cultured human intestinal stem cells</article-title><source>Nature</source><volume>521</volume><fpage>43</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1038/nature14415</pub-id><pub-id pub-id-type="pmid">25924068</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>KW</given-names></name><name><surname>Das</surname><given-names>B</given-names></name><name><surname>Kortum</surname><given-names>RL</given-names></name><name><surname>Chaika</surname><given-names>OV</given-names></name><name><surname>Lewis</surname><given-names>RE</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Kinase suppressor of ras 1 (KSR1) regulates PGC1α and estrogen-related receptor α to promote oncogenic Ras-dependent anchorage-independent growth</article-title><source>Molecular and Cellular Biology</source><volume>31</volume><fpage>2453</fpage><lpage>2461</lpage><pub-id pub-id-type="doi">10.1128/MCB.05255-11</pub-id><pub-id pub-id-type="pmid">21518958</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>KW</given-names></name><name><surname>Das</surname><given-names>B</given-names></name><name><surname>Kim</surname><given-names>HS</given-names></name><name><surname>Clymer</surname><given-names>BK</given-names></name><name><surname>Gehring</surname><given-names>D</given-names></name><name><surname>Smith</surname><given-names>DR</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>AMPK Promotes Aberrant PGC1β Expression To Support Human Colon Tumor Cell Survival</article-title><source>Molecular and Cellular Biology</source><volume>35</volume><fpage>3866</fpage><lpage>3879</lpage><pub-id pub-id-type="doi">10.1128/MCB.00528-15</pub-id><pub-id pub-id-type="pmid">26351140</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frixen</surname><given-names>UH</given-names></name><name><surname>Behrens</surname><given-names>J</given-names></name><name><surname>Sachs</surname><given-names>M</given-names></name><name><surname>Eberle</surname><given-names>G</given-names></name><name><surname>Voss</surname><given-names>B</given-names></name><name><surname>Warda</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells</article-title><source>The Journal of Cell Biology</source><volume>113</volume><fpage>173</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1083/jcb.113.1.173</pub-id><pub-id pub-id-type="pmid">2007622</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haigis</surname><given-names>KM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>KRAS Alleles: The Devil Is in the Detail</article-title><source>Trends in Cancer</source><volume>3</volume><fpage>686</fpage><lpage>697</lpage><pub-id pub-id-type="doi">10.1016/j.trecan.2017.08.006</pub-id><pub-id pub-id-type="pmid">28958387</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hulit</surname><given-names>J</given-names></name><name><surname>Suyama</surname><given-names>K</given-names></name><name><surname>Chung</surname><given-names>S</given-names></name><name><surname>Keren</surname><given-names>R</given-names></name><name><surname>Agiostratidou</surname><given-names>G</given-names></name><name><surname>Shan</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>N-cadherin signaling potentiates mammary tumor metastasis via enhanced extracellular signal-regulated kinase activation</article-title><source>Cancer Research</source><volume>67</volume><fpage>3106</fpage><lpage>3116</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-3401</pub-id><pub-id pub-id-type="pmid">17409417</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jechlinger</surname><given-names>M</given-names></name><name><surname>Grunert</surname><given-names>S</given-names></name><name><surname>Tamir</surname><given-names>IH</given-names></name><name><surname>Janda</surname><given-names>E</given-names></name><name><surname>Ludemann</surname><given-names>S</given-names></name><name><surname>Waerner</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Expression profiling of epithelial plasticity in tumor progression</article-title><source>Oncogene</source><volume>22</volume><fpage>7155</fpage><lpage>7169</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1206887</pub-id><pub-id pub-id-type="pmid">14562044</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnston</surname><given-names>ST</given-names></name><name><surname>Shah</surname><given-names>ET</given-names></name><name><surname>Chopin</surname><given-names>LK</given-names></name><name><surname>Sean McElwain</surname><given-names>DL</given-names></name><name><surname>Simpson</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Estimating cell diffusivity and cell proliferation rate by interpreting IncuCyte ZOOM assay data using the Fisher-Kolmogorov model</article-title><source>BMC Systems Biology</source><volume>9</volume><elocation-id>38</elocation-id><pub-id pub-id-type="doi">10.1186/s12918-015-0182-y</pub-id><pub-id pub-id-type="pmid">26188761</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jolly</surname><given-names>MK</given-names></name><name><surname>Ware</surname><given-names>KE</given-names></name><name><surname>Gilja</surname><given-names>S</given-names></name><name><surname>Somarelli</surname><given-names>JA</given-names></name><name><surname>Levine</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>EMT and MET: Necessary or permissive for metastasis?</article-title><source>Molecular Oncology</source><volume>11</volume><fpage>755</fpage><lpage>769</lpage><pub-id pub-id-type="doi">10.1002/1878-0261.12083</pub-id><pub-id pub-id-type="pmid">28548345</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>YH</given-names></name><name><surname>Lee</surname><given-names>JR</given-names></name><name><surname>Hahn</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Regulation of inflammatory gene expression in macrophages by epithelial-stromal interaction 1 (Epsti1</article-title><source>Biochemical and Biophysical Research Communications</source><volume>496</volume><fpage>778</fpage><lpage>783</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2017.12.014</pub-id><pub-id pub-id-type="pmid">29217193</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>King</surname><given-names>HA</given-names></name><name><surname>Gerber</surname><given-names>AP</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Translatome profiling: methods for genome-scale analysis of mRNA translation</article-title><source>Briefings in Functional Genomics</source><volume>15</volume><fpage>22</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1093/bfgp/elu045</pub-id><pub-id pub-id-type="pmid">25380596</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kortum</surname><given-names>RL</given-names></name><name><surname>Lewis</surname><given-names>RE</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>The molecular scaffold KSR1 regulates the proliferative and oncogenic potential of cells</article-title><source>Molecular and Cellular Biology</source><volume>24</volume><fpage>4407</fpage><lpage>4416</lpage><pub-id pub-id-type="doi">10.1128/MCB.24.10.4407-4416.2004</pub-id><pub-id pub-id-type="pmid">15121859</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kortum</surname><given-names>RL</given-names></name><name><surname>Johnson</surname><given-names>HJ</given-names></name><name><surname>Costanzo</surname><given-names>DL</given-names></name><name><surname>Volle</surname><given-names>DJ</given-names></name><name><surname>Razidlo</surname><given-names>GL</given-names></name><name><surname>Fusello</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The molecular scaffold kinase suppressor of Ras 1 is a modifier of RasV12-induced and replicative senescence</article-title><source>Molecular and Cellular Biology</source><volume>26</volume><fpage>2202</fpage><lpage>2214</lpage><pub-id pub-id-type="doi">10.1128/MCB.26.6.2202-2214.2006</pub-id><pub-id pub-id-type="pmid">16507997</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemieux</surname><given-names>E</given-names></name><name><surname>Bergeron</surname><given-names>S</given-names></name><name><surname>Durand</surname><given-names>V</given-names></name><name><surname>Asselin</surname><given-names>C</given-names></name><name><surname>Saucier</surname><given-names>C</given-names></name><name><surname>Rivard</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Constitutively active MEK1 is sufficient to induce epithelial-to-mesenchymal transition in intestinal epithelial cells and to promote tumor invasion and metastasis</article-title><source>International Journal of Cancer</source><volume>125</volume><fpage>1575</fpage><lpage>1586</lpage><pub-id pub-id-type="doi">10.1002/ijc.24485</pub-id><pub-id pub-id-type="pmid">19462441</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Lu</surname><given-names>H</given-names></name><name><surname>Shen</surname><given-names>C</given-names></name><name><surname>Lahiri</surname><given-names>SK</given-names></name><name><surname>Wason</surname><given-names>MS</given-names></name><name><surname>Mukherjee</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Identification of epithelial stromal interaction 1 as a novel effector downstream of Krüppel-like factor 8 in breast cancer invasion and metastasis</article-title><source>Oncogene</source><volume>33</volume><fpage>4746</fpage><lpage>4755</lpage><pub-id pub-id-type="doi">10.1038/onc.2013.415</pub-id><pub-id pub-id-type="pmid">24096480</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Sanchez-Tillo</surname><given-names>E</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Clem</surname><given-names>B</given-names></name><name><surname>Telang</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The ZEB1 transcription factor acts in a negative feedback loop with miR200 downstream of Ras and Rb1 to regulate Bmi1 expression</article-title><source>The Journal of Biological Chemistry</source><volume>289</volume><fpage>4116</fpage><lpage>4125</lpage><pub-id pub-id-type="doi">10.1074/jbc.M113.533505</pub-id><pub-id pub-id-type="pmid">24371144</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>C-C</given-names></name><name><surname>Cai</surname><given-names>D-L</given-names></name><name><surname>Sun</surname><given-names>F</given-names></name><name><surname>Wu</surname><given-names>Z-H</given-names></name><name><surname>Yue</surname><given-names>B</given-names></name><name><surname>Zhao</surname><given-names>S-L</given-names></name><name><surname>Wu</surname><given-names>X-S</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Zhu</surname><given-names>X-W</given-names></name><name><surname>Peng</surname><given-names>Z-H</given-names></name><name><surname>Yan</surname><given-names>D-W</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>FERMT1 mediates epithelial-mesenchymal transition to promote colon cancer metastasis via modulation of β-catenin transcriptional activity</article-title><source>Oncogene</source><volume>36</volume><fpage>1779</fpage><lpage>1792</lpage><pub-id pub-id-type="doi">10.1038/onc.2016.339</pub-id><pub-id pub-id-type="pmid">27641329</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loh</surname><given-names>CY</given-names></name><name><surname>Chai</surname><given-names>JY</given-names></name><name><surname>Tang</surname><given-names>TF</given-names></name><name><surname>Wong</surname><given-names>WF</given-names></name><name><surname>Sethi</surname><given-names>G</given-names></name><name><surname>Shanmugam</surname><given-names>MK</given-names></name><name><surname>Chong</surname><given-names>PP</given-names></name><name><surname>Looi</surname><given-names>CY</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The e-cadherin and n-cadherin switch in epithelial-to-mesenchymal transition: Signaling, therapeutic implications, and challenges</article-title><source>Cells</source><volume>8</volume><elocation-id>1118</elocation-id><pub-id pub-id-type="doi">10.3390/cells8101118</pub-id><pub-id pub-id-type="pmid">31547193</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Longo</surname><given-names>PA</given-names></name><name><surname>Kavran</surname><given-names>JM</given-names></name><name><surname>Kim</surname><given-names>MS</given-names></name><name><surname>Leahy</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Transient mammalian cell transfection with polyethylenimine (PEI</article-title><source>Methods Enzymol</source><volume>529</volume><fpage>227</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-418687-3.00018-5</pub-id><pub-id pub-id-type="pmid">24011049</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lozano</surname><given-names>J</given-names></name><name><surname>Xing</surname><given-names>R</given-names></name><name><surname>Cai</surname><given-names>Z</given-names></name><name><surname>Jensen</surname><given-names>HL</given-names></name><name><surname>Trempus</surname><given-names>C</given-names></name><name><surname>Mark</surname><given-names>W</given-names></name><name><surname>Cannon</surname><given-names>R</given-names></name><name><surname>Kolesnick</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Deficiency of kinase suppressor of ras1 prevents oncogenic RAS signaling in mice</article-title><source>Cancer Research</source><volume>63</volume><fpage>4232</fpage><lpage>4238</lpage><pub-id pub-id-type="pmid">12874031</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maeda</surname><given-names>M</given-names></name><name><surname>Johnson</surname><given-names>KR</given-names></name><name><surname>Wheelock</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Cadherin switching: essential for behavioral but not morphological changes during an epithelium-to-mesenchyme transition</article-title><source>Journal of Cell Science</source><volume>118</volume><fpage>873</fpage><lpage>887</lpage><pub-id pub-id-type="doi">10.1242/jcs.01634</pub-id><pub-id pub-id-type="pmid">15713751</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCall</surname><given-names>JL</given-names></name><name><surname>Gehring</surname><given-names>D</given-names></name><name><surname>Clymer</surname><given-names>BK</given-names></name><name><surname>Fisher</surname><given-names>KW</given-names></name><name><surname>Das</surname><given-names>B</given-names></name><name><surname>Kelly</surname><given-names>DL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>KSR1 and EPHB4 Regulate Myc and PGC1β To Promote Survival of Human Colon Tumors</article-title><source>Molecular and Cellular Biology</source><volume>36</volume><fpage>2246</fpage><lpage>2261</lpage><pub-id pub-id-type="doi">10.1128/MCB.00087-16</pub-id><pub-id pub-id-type="pmid">27273865</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>EJ</given-names></name><name><surname>Jha</surname><given-names>S</given-names></name><name><surname>Restaino</surname><given-names>CR</given-names></name><name><surname>Dayananth</surname><given-names>P</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Cooper</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors</article-title><source>Cancer Discovery</source><volume>3</volume><fpage>742</fpage><lpage>750</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-13-0070</pub-id><pub-id pub-id-type="pmid">23614898</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morrison</surname><given-names>DK</given-names></name><name><surname>Davis</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Regulation of map kinase signaling modules by scaffold proteins in mammals</article-title><source>Annual Review of Cell and Developmental Biology</source><volume>19</volume><fpage>91</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1146/annurev.cellbio.19.111401.091942</pub-id><pub-id pub-id-type="pmid">14570565</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morrison</surname><given-names>MMM</given-names></name><name><surname>Daniel</surname><given-names>AR</given-names></name><name><surname>Deborah</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Signaling dynamics of the ksr1 scaffold complex</article-title><source>PNAS</source><volume>106</volume><fpage>11022</fpage><lpage>11027</lpage><pub-id pub-id-type="doi">10.1073/pnas.0901590106</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mrozik</surname><given-names>KM</given-names></name><name><surname>Blaschuk</surname><given-names>OW</given-names></name><name><surname>Cheong</surname><given-names>CM</given-names></name><name><surname>Zannettino</surname><given-names>ACW</given-names></name><name><surname>Vandyke</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>N-cadherin in cancer metastasis, its emerging role in haematological malignancies and potential as a therapeutic target in cancer</article-title><source>BMC Cancer</source><volume>18</volume><elocation-id>939</elocation-id><pub-id pub-id-type="doi">10.1186/s12885-018-4845-0</pub-id><pub-id pub-id-type="pmid">30285678</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neilsen</surname><given-names>BK</given-names></name><name><surname>Frodyma</surname><given-names>DE</given-names></name><name><surname>McCall</surname><given-names>JL</given-names></name><name><surname>Fisher</surname><given-names>KW</given-names></name><name><surname>Lewis</surname><given-names>RE</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>ERK-mediated TIMELESS expression suppresses G2/M arrest in colon cancer cells</article-title><source>PLOS ONE</source><volume>14</volume><elocation-id>e0209224</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0209224</pub-id><pub-id pub-id-type="pmid">30629587</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>A</given-names></name><name><surname>Burack</surname><given-names>WR</given-names></name><name><surname>Stock</surname><given-names>JL</given-names></name><name><surname>Kortum</surname><given-names>R</given-names></name><name><surname>Chaika</surname><given-names>OV</given-names></name><name><surname>Afkarian</surname><given-names>M</given-names></name><name><surname>Muller</surname><given-names>WJ</given-names></name><name><surname>Murphy</surname><given-names>KM</given-names></name><name><surname>Morrison</surname><given-names>DK</given-names></name><name><surname>Lewis</surname><given-names>RE</given-names></name><name><surname>McNeish</surname><given-names>J</given-names></name><name><surname>Shaw</surname><given-names>AS</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Kinase suppressor of ras (KSR) is a scaffold which facilitates mitogen-activated protein kinase activation in vivo</article-title><source>Molecular and Cellular Biology</source><volume>22</volume><fpage>3035</fpage><lpage>3045</lpage><pub-id pub-id-type="doi">10.1128/mcb.22.9.3035-3045.2002</pub-id><pub-id pub-id-type="pmid">11940661</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nielsen</surname><given-names>HL</given-names></name><name><surname>Ronnov-Jessen</surname><given-names>L</given-names></name><name><surname>Villadsen</surname><given-names>R</given-names></name><name><surname>Petersen</surname><given-names>OW</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Identification of epsti1, a novel gene induced by epithelial-stromal interaction in human breast cancer</article-title><source>Genomics</source><volume>79</volume><fpage>703</fpage><lpage>710</lpage><pub-id pub-id-type="doi">10.1006/geno.2002.6755</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nieman</surname><given-names>MT</given-names></name><name><surname>Prudoff</surname><given-names>RS</given-names></name><name><surname>Johnson</surname><given-names>KR</given-names></name><name><surname>Wheelock</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression</article-title><source>The Journal of Cell Biology</source><volume>147</volume><fpage>631</fpage><lpage>644</lpage><pub-id pub-id-type="doi">10.1083/jcb.147.3.631</pub-id><pub-id pub-id-type="pmid">10545506</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nieto</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Epithelial plasticity: a common theme in embryonic and cancer cells</article-title><source>Science</source><volume>342</volume><elocation-id>1234850</elocation-id><pub-id pub-id-type="doi">10.1126/science.1234850</pub-id><pub-id pub-id-type="pmid">24202173</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nieto</surname><given-names>MA</given-names></name><name><surname>Huang</surname><given-names>RY</given-names></name><name><surname>Jackson</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Thiery JP EMT: 2016</article-title><source>Cell</source><volume>10</volume><fpage>21</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.06.028</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oda</surname><given-names>T</given-names></name><name><surname>Kanai</surname><given-names>Y</given-names></name><name><surname>Oyama</surname><given-names>T</given-names></name><name><surname>Yoshiura</surname><given-names>K</given-names></name><name><surname>Shimoyama</surname><given-names>Y</given-names></name><name><surname>Birchmeier</surname><given-names>W</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>E-cadherin gene mutations in human gastric carcinoma cell lines</article-title><source>PNAS</source><volume>91</volume><fpage>1858</fpage><lpage>1862</lpage><pub-id pub-id-type="doi">10.1073/pnas.91.5.1858</pub-id><pub-id pub-id-type="pmid">8127895</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oertlin</surname><given-names>C</given-names></name><name><surname>Lorent</surname><given-names>J</given-names></name><name><surname>Murie</surname><given-names>C</given-names></name><name><surname>Furic</surname><given-names>L</given-names></name><name><surname>Topisirovic</surname><given-names>I</given-names></name><name><surname>Larsson</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Generally applicable transcriptome-wide analysis of translation using anota2seq</article-title><source>Nucleic Acids Research</source><volume>47</volume><elocation-id>e70</elocation-id><pub-id pub-id-type="doi">10.1093/nar/gkz223</pub-id><pub-id pub-id-type="pmid">30926999</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okubo</surname><given-names>K</given-names></name><name><surname>Uenosono</surname><given-names>Y</given-names></name><name><surname>Arigami</surname><given-names>T</given-names></name><name><surname>Yanagita</surname><given-names>S</given-names></name><name><surname>Matsushita</surname><given-names>D</given-names></name><name><surname>Kijima</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Clinical significance of altering epithelial-mesenchymal transition in metastatic lymph nodes of gastric cancer</article-title><source>Gastric Cancer</source><volume>20</volume><fpage>802</fpage><lpage>810</lpage><pub-id pub-id-type="doi">10.1007/s10120-017-0705-x</pub-id><pub-id pub-id-type="pmid">28247164</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Onder</surname><given-names>TT</given-names></name><name><surname>Gupta</surname><given-names>PB</given-names></name><name><surname>Mani</surname><given-names>SA</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways</article-title><source>Cancer Research</source><volume>68</volume><fpage>3645</fpage><lpage>3654</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-2938</pub-id><pub-id pub-id-type="pmid">18483246</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>S</given-names></name><name><surname>Brugiolo</surname><given-names>M</given-names></name><name><surname>Akerman</surname><given-names>M</given-names></name><name><surname>Das</surname><given-names>S</given-names></name><name><surname>Urbanski</surname><given-names>L</given-names></name><name><surname>Geier</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Differential Functions of Splicing Factors in Mammary Transformation and Breast Cancer Metastasis</article-title><source>Cell Reports</source><volume>29</volume><fpage>2672</fpage><lpage>2688</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2019.10.110</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pawson</surname><given-names>T</given-names></name><name><surname>Scott</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Signaling through scaffold, anchoring, and adaptor proteins</article-title><source>Science</source><volume>278</volume><fpage>2075</fpage><lpage>2080</lpage><pub-id pub-id-type="doi">10.1126/science.278.5346.2075</pub-id><pub-id pub-id-type="pmid">9405336</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pelletier</surname><given-names>J</given-names></name><name><surname>Graff</surname><given-names>J</given-names></name><name><surname>Ruggero</surname><given-names>D</given-names></name><name><surname>Sonenberg</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Targeting the eIF4F translation initiation complex: a critical nexus for cancer development</article-title><source>Cancer Research</source><volume>75</volume><fpage>250</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-14-2789</pub-id><pub-id pub-id-type="pmid">25593033</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pradella</surname><given-names>D</given-names></name><name><surname>Naro</surname><given-names>C</given-names></name><name><surname>Sette</surname><given-names>C</given-names></name><name><surname>Ghigna</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>EMT and stemness: flexible processes tuned by alternative splicing in development and cancer progression</article-title><source>Molecular Cancer</source><volume>16</volume><elocation-id>8</elocation-id><pub-id pub-id-type="doi">10.1186/s12943-016-0579-2</pub-id><pub-id pub-id-type="pmid">28137272</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prakash</surname><given-names>V</given-names></name><name><surname>Carson</surname><given-names>BB</given-names></name><name><surname>Feenstra</surname><given-names>JM</given-names></name><name><surname>Dass</surname><given-names>RA</given-names></name><name><surname>Sekyrova</surname><given-names>P</given-names></name><name><surname>Hoshino</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Ribosome biogenesis during cell cycle arrest fuels EMT in development and disease</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>2110</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-10100-8</pub-id><pub-id pub-id-type="pmid">31068593</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>C</given-names></name><name><surname>Huisman</surname><given-names>DH</given-names></name><name><surname>Vieira</surname><given-names>HM</given-names></name><name><surname>Frodyma</surname><given-names>DE</given-names></name><name><surname>Neilsen</surname><given-names>BK</given-names></name><name><surname>Chakraborty</surname><given-names>B</given-names></name><name><surname>Hight</surname><given-names>SK</given-names></name><name><surname>White</surname><given-names>MA</given-names></name><name><surname>Fisher</surname><given-names>KW</given-names></name><name><surname>Lewis</surname><given-names>RE</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A gene expression high-throughput screen (GE-HTS) for coordinated detection of functionally similar effectors in cancer</article-title><source>Cancers</source><volume>12</volume><elocation-id>3143</elocation-id><pub-id pub-id-type="doi">10.3390/cancers12113143</pub-id><pub-id pub-id-type="pmid">33120942</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roig</surname><given-names>AI</given-names></name><name><surname>Eskiocak</surname><given-names>U</given-names></name><name><surname>Hight</surname><given-names>SK</given-names></name><name><surname>Kim</surname><given-names>SB</given-names></name><name><surname>Delgado</surname><given-names>O</given-names></name><name><surname>Souza</surname><given-names>RF</given-names></name><name><surname>Spechler</surname><given-names>SJ</given-names></name><name><surname>Wright</surname><given-names>WE</given-names></name><name><surname>Shay</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Immortalized epithelial cells derived from human colon biopsies express stem cell markers and differentiate in vitro</article-title><source>Gastroenterology</source><volume>138</volume><fpage>1012</fpage><lpage>1021</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2009.11.052</pub-id><pub-id pub-id-type="pmid">19962984</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosivatz</surname><given-names>E</given-names></name><name><surname>Becker</surname><given-names>I</given-names></name><name><surname>Bamba</surname><given-names>M</given-names></name><name><surname>Schott</surname><given-names>C</given-names></name><name><surname>Diebold</surname><given-names>J</given-names></name><name><surname>Mayr</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Neoexpression of N-cadherin in E-cadherin positive colon cancers</article-title><source>International Journal of Cancer</source><volume>111</volume><fpage>711</fpage><lpage>719</lpage><pub-id pub-id-type="doi">10.1002/ijc.20317</pub-id><pub-id pub-id-type="pmid">15252840</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roux</surname><given-names>PP</given-names></name><name><surname>Shahbazian</surname><given-names>D</given-names></name><name><surname>Vu</surname><given-names>H</given-names></name><name><surname>Holz</surname><given-names>MK</given-names></name><name><surname>Cohen</surname><given-names>MS</given-names></name><name><surname>Taunton</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation</article-title><source>The Journal of Biological Chemistry</source><volume>282</volume><fpage>14056</fpage><lpage>14064</lpage><pub-id pub-id-type="doi">10.1074/jbc.M700906200</pub-id><pub-id pub-id-type="pmid">17360704</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadot</surname><given-names>E</given-names></name><name><surname>Simcha</surname><given-names>I</given-names></name><name><surname>Shtutman</surname><given-names>M</given-names></name><name><surname>Ben-Ze’ev</surname><given-names>A</given-names></name><name><surname>Geiger</surname><given-names>B</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Inhibition of beta-catenin-mediated transactivation by cadherin derivatives</article-title><source>PNAS</source><volume>95</volume><fpage>15339</fpage><lpage>15344</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.26.15339</pub-id><pub-id pub-id-type="pmid">9860970</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scarpa</surname><given-names>E</given-names></name><name><surname>Szabo</surname><given-names>A</given-names></name><name><surname>Bibonne</surname><given-names>A</given-names></name><name><surname>Theveneau</surname><given-names>E</given-names></name><name><surname>Parsons</surname><given-names>M</given-names></name><name><surname>Mayor</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Cadherin Switch during EMT in Neural Crest Cells Leads to Contact Inhibition of Locomotion via Repolarization of Forces</article-title><source>Developmental Cell</source><volume>34</volume><fpage>421</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2015.06.012</pub-id><pub-id pub-id-type="pmid">26235046</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmittgen</surname><given-names>TD</given-names></name><name><surname>Livak</surname><given-names>KJ</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Analyzing real-time PCR data by the comparative C(T) method</article-title><source>Nature Protocols</source><volume>3</volume><fpage>1101</fpage><lpage>1108</lpage><pub-id pub-id-type="doi">10.1038/nprot.2008.73</pub-id><pub-id pub-id-type="pmid">18546601</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmitz</surname><given-names>KJ</given-names></name><name><surname>Wohlschlaeger</surname><given-names>J</given-names></name><name><surname>Alakus</surname><given-names>H</given-names></name><name><surname>Bohr</surname><given-names>J</given-names></name><name><surname>Stauder</surname><given-names>MA</given-names></name><name><surname>Worm</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Activation of extracellular regulated kinases (ERK1/2) but not AKT predicts poor prognosis in colorectal carcinoma and is associated with k-ras mutations</article-title><source>Virchows Archiv</source><volume>450</volume><fpage>151</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1007/s00428-006-0342-y</pub-id><pub-id pub-id-type="pmid">17149612</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serebriiskii</surname><given-names>IG</given-names></name><name><surname>Connelly</surname><given-names>C</given-names></name><name><surname>Frampton</surname><given-names>G</given-names></name><name><surname>Newberg</surname><given-names>J</given-names></name><name><surname>Cooke</surname><given-names>M</given-names></name><name><surname>Miller</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Comprehensive characterization of ras mutations in colon and rectal cancers in old and young patients</article-title><source>Nature Communications</source><volume>110</volume><elocation-id>3722</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-11530-0</pub-id><pub-id pub-id-type="pmid">31427573</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>S</given-names></name><name><surname>Dimitri</surname><given-names>CA</given-names></name><name><surname>Yoon</surname><given-names>SO</given-names></name><name><surname>Dowdle</surname><given-names>W</given-names></name><name><surname>Blenis</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>ERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via DEF motif-dependent signaling events</article-title><source>Molecular Cell</source><volume>38</volume><fpage>114</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2010.02.020</pub-id><pub-id pub-id-type="pmid">20385094</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>S</given-names></name><name><surname>Buel</surname><given-names>GR</given-names></name><name><surname>Nagiec</surname><given-names>MJ</given-names></name><name><surname>Han</surname><given-names>MJ</given-names></name><name><surname>Roux</surname><given-names>PP</given-names></name><name><surname>Blenis</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>ERK2 regulates epithelial-to-mesenchymal plasticity through DOCK10-dependent Rac1/FoxO1 activation</article-title><source>PNAS</source><volume>116</volume><fpage>2967</fpage><lpage>2976</lpage><pub-id pub-id-type="doi">10.1073/pnas.1811923116</pub-id><pub-id pub-id-type="pmid">30728292</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stevens</surname><given-names>PD</given-names></name><name><surname>Wen</surname><given-names>Y-A</given-names></name><name><surname>Xiong</surname><given-names>X</given-names></name><name><surname>Zaytseva</surname><given-names>YY</given-names></name><name><surname>Li</surname><given-names>AT</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Erbin Suppresses KSR1-Mediated RAS/RAF Signaling and Tumorigenesis in Colorectal Cancer</article-title><source>Cancer Research</source><volume>78</volume><fpage>4839</fpage><lpage>4852</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-17-3629</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Mootha</surname><given-names>VK</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Ebert</surname><given-names>BL</given-names></name><name><surname>Gillette</surname><given-names>MA</given-names></name><name><surname>Paulovich</surname><given-names>A</given-names></name><name><surname>Pomeroy</surname><given-names>SL</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles</article-title><source>PNAS</source><volume>102</volume><fpage>15545</fpage><lpage>15550</lpage><pub-id pub-id-type="doi">10.1073/pnas.0506580102</pub-id><pub-id pub-id-type="pmid">16199517</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suyama</surname><given-names>K</given-names></name><name><surname>Shapiro</surname><given-names>I</given-names></name><name><surname>Guttman</surname><given-names>M</given-names></name><name><surname>Hazan</surname><given-names>RB</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>A signaling pathway leading to metastasis is controlled by N-cadherin and the FGF receptor</article-title><source>Cancer Cell</source><volume>2</volume><fpage>301</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1016/s1535-6108(02)00150-2</pub-id><pub-id pub-id-type="pmid">12398894</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thiery</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Epithelial-mesenchymal transitions in tumour progression</article-title><source>Nature Reviews. Cancer</source><volume>2</volume><fpage>442</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1038/nrc822</pub-id><pub-id pub-id-type="pmid">12189386</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thiery</surname><given-names>JP</given-names></name><name><surname>Acloque</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>RY</given-names></name><name><surname>Nieto</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Epithelial-mesenchymal transitions in development and disease</article-title><source>Cell</source><volume>139</volume><fpage>871</fpage><lpage>890</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.11.007</pub-id><pub-id pub-id-type="pmid">19945376</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomita</surname><given-names>K</given-names></name><name><surname>van Bokhoven</surname><given-names>A</given-names></name><name><surname>van Leenders</surname><given-names>GJ</given-names></name><name><surname>Ruijter</surname><given-names>ET</given-names></name><name><surname>Jansen</surname><given-names>CF</given-names></name><name><surname>Bussemakers</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Cadherin switching in human prostate cancer progression</article-title><source>Cancer Research</source><volume>60</volume><fpage>3650</fpage><lpage>3654</lpage><pub-id pub-id-type="pmid">10910081</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Truitt</surname><given-names>ML</given-names></name><name><surname>Ruggero</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>New frontiers in translational control of the cancer genome</article-title><source>Nature Reviews. Cancer</source><volume>16</volume><fpage>288</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1038/nrc.2016.27</pub-id><pub-id pub-id-type="pmid">27112207</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Truitt Morgan</surname><given-names>L</given-names></name><name><surname>Conn Crystal</surname><given-names>S</given-names></name><name><surname>Shi</surname><given-names>Z</given-names></name><name><surname>Pang</surname><given-names>X</given-names></name><name><surname>Tokuyasu</surname><given-names>T</given-names></name><name><surname>Coady Alison</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Differential requirements for EIF4E dose in normal development and cancer</article-title><source>Cell</source><volume>162</volume><fpage>59</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.05.049</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van de Wetering</surname><given-names>M</given-names></name><name><surname>Francies</surname><given-names>HE</given-names></name><name><surname>Francis</surname><given-names>JM</given-names></name><name><surname>Bounova</surname><given-names>G</given-names></name><name><surname>Iorio</surname><given-names>F</given-names></name><name><surname>Pronk</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Prospective derivation of a living organoid biobank of colorectal cancer patients</article-title><source>Cell</source><volume>161</volume><fpage>933</fpage><lpage>945</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.03.053</pub-id><pub-id pub-id-type="pmid">25957691</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waerner</surname><given-names>T</given-names></name><name><surname>Alacakaptan</surname><given-names>M</given-names></name><name><surname>Tamir</surname><given-names>I</given-names></name><name><surname>Oberauer</surname><given-names>R</given-names></name><name><surname>Gal</surname><given-names>A</given-names></name><name><surname>Brabletz</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>ILEI: a cytokine essential for EMT, tumor formation, and late events in metastasis in epithelial cells</article-title><source>Cancer Cell</source><volume>10</volume><fpage>227</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2006.07.020</pub-id><pub-id pub-id-type="pmid">16959614</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Ngo</surname><given-names>VN</given-names></name><name><surname>Marani</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Wright</surname><given-names>G</given-names></name><name><surname>Staudt</surname><given-names>LM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Critical role for transcriptional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells</article-title><source>Oncogene</source><volume>29</volume><fpage>4658</fpage><lpage>4670</lpage><pub-id pub-id-type="doi">10.1038/onc.2010.218</pub-id><pub-id pub-id-type="pmid">20562906</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wheelock</surname><given-names>MJ</given-names></name><name><surname>Shintani</surname><given-names>Y</given-names></name><name><surname>Maeda</surname><given-names>M</given-names></name><name><surname>Fukumoto</surname><given-names>Y</given-names></name><name><surname>Johnson</surname><given-names>KR</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Cadherin switching</article-title><source>Journal of Cell Science</source><volume>121</volume><fpage>727</fpage><lpage>735</lpage><pub-id pub-id-type="doi">10.1242/jcs.000455</pub-id><pub-id pub-id-type="pmid">18322269</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>CE</given-names></name><name><surname>Yu</surname><given-names>JS</given-names></name><name><surname>Quigley</surname><given-names>DA</given-names></name><name><surname>Jen</surname><given-names>KY</given-names></name><name><surname>Huang</surname><given-names>PY</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Inflammation and hras signaling control epithelial-mesenchymal transition during skin tumor progression</article-title><source>Genes &amp; Development</source><volume>27</volume><fpage>670</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1101/gad.210427.112</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>X</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Epithelial-Mesenchymal Plasticity: A Central Regulator of Cancer Progression</article-title><source>Trends in Cell Biology</source><volume>25</volume><fpage>675</fpage><lpage>686</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2015.07.012</pub-id><pub-id pub-id-type="pmid">26437589</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.66608.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Sonenberg</surname><given-names>Nahum</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01pxwe438</institution-id><institution>McGill University</institution></institution-wrap><country>Canada</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Davis</surname><given-names>Roger J</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0464eyp60</institution-id><institution>University of Massachusetts Medical School</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2021.01.18.427224">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2021.01.18.427224v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>This paper demonstrates the involvement of Kinase Suppressor of Ras 1 (KSR1), a protein that acts as a scaffold in the mitogen-activated protein kinase (MAPK) signaling cascade, in translational control of the epithelial-to-mesenchymal transition. The analysis is thorough and includes both loss-of-function and gain-of-function studies. This study advances our understanding of cancer development.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;KSR1-and ERK-dependent Translational Regulation of the Epithelial-to-Mesenchymal Transition&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Jonathan Cooper as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Roger J Davis (Reviewer #3).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>While the reviewers found that the paper provides convincing evidence for the role of EPSTl1 in KSR1-dependent EMT, 2 of the reviewers raised valid criticisms concerning the lack of experiments to exclude an effect on degradation of EPSTl1, an important technical problem with the polysome versus monosome assignment (which could affect the interpretation of the data), and overstatements of the data. Following discussions among the referees, it was agreed that an in vivo model of colon cancer to reproduce the in vitro phenotype (as requested by reviewer #2) is not necessary for this paper. We include the full reviews of the referees because they contain in addition to the necessary changes, some very constructive suggestions for improvement of the paper.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>1. The authors should rule out that KSR KD or KO does not impact EPSTI1 protein degradation.</p><p>2. Lines 166-167 – the authors state that KSR1-dependent translation of EPSTI1 is required for colon tumor cell transformation. First, tumor cells do not transform. They are already transformed. Second, no experiments up to this point show that EPSTI1 is required for transformation. To demonstrate this, they would need to express EPSTI1 in a normal or immortalized cell and demonstrate its ability to induce anchorage independent growth, or soft agar growth, or the ability to form tumors in mice. The experiments in figure 3 demonstrate that EPSTI1 is increased in colon cancer cell lines compared to &quot;normal&quot; cells and that KD of EPSTI1 in colon cancer cells leads to decreased viability and colony formation. Together these experiments prove that EPSTI1 is necessary for established cancer cell growth, but not transformation as stated.</p><p>3. Figure 4 – With regards to the impact of EPSTI1 KD or KO on cell migration, the authors should consider measuring the impact of EPSTI1 KD or KO on cell proliferation, since this could have a significant impact on the interpretation of the wound healing assay and Matrigel invasion assay. If there is no difference in proliferation then the authors' assertion that EPSTI1 is necessary for the migratory potential of the CRC cell lines hold true. However, if KD or KO cells are proliferating less (as supported by their previous work), then another reason the cells may appear to be closing the gap slower, or invading through Matrigel slower, is a decrease in cell cycle progression. If this is the case, the authors can still make the argument that EPSTI1 KD or KO cells move slower if they conduct realtime imaging of individual cells and track their movement (can be shown as a spider plot).</p><p>4. Lines 196-198 – the authors state that &quot;the switch of E-cadherin to N-cadherin expression promotes the progression of migratory and invasive behavior orchestrated by KSR1-EPSTI1 signaling in CRC cells.&quot; This is an overstatement based on the evidence provided in Figure 5. The authors demonstrate that a switch in E-cad and N-cad are associated with migratory potential, but do not demonstrate that the switch actually promotes the progression. In order to do this, they would need to KD E-cad and/or overexpress N-cad and demonstrate that this can rescue the decrease in cell migration see in Figure 4.</p><p>5. Figure 6 – Does the enforced expression of EPSTI1 increase proliferation in these cells? If so, would consider comments in point #2.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>1. The data shown to support the conclusion that the regulation of EPSTI1 by KSR1 is under translational control requires clarification. Authors state in the methods that RNAseq was performed on: &quot;total RNA and RNA pooled from the polysome fraction (fractions 6-9)&quot;. According to the absorbance profile shown in figure 1A, fractions 6-9 would not correspond to efficiently translated mRNAs (i.e. bound by 3 or more ribosomes), it looks like fraction 6 is the monosome. Can the authors please clarify, as this is an important technical concern which is of course relevant to the RNA-seq analysis that the authors performed to identify EPSTI1 (and potentially other targets listed) as being under translational control. Related comment regarding Figure 1F, the comparison being made is not entirely clear, the difference between control cells and the KSR1 knock-downs seems to only be obvious in one fraction, #7, which from the absorbance profile seems to be a &quot;light fraction&quot;.</p><p>2. Data with SCH772984 supports the importance of ERK1/2 activation in the regulation of EPSTI1 protein expression. However, the data that ERK1/2 inhibition alters the translation of EPSTI1 mRNA is not robust. The absorbance profiles related to the polysome fractionation done on HCT116 cells treated or not with SCH772984 are unusual, and thus the data shown in Figure 2E are in question. Related to EPSTI1 expression being under translational control, can its translation be repressed by an inhibitor of mTOR?</p><p>3. The authors have shown data that the KSR1-dependent regulation of EPSTI1 is essential for EMT, including effects on invasion, anchorage-independent cell viability, and the cadherin switch in colon cancer cell lines depleted of KSR1 (and phenotypes are rescued with add-backs of KSR1 or EPSTI1). Missing from the manuscript is an in vivo model to show whether the observed in vitro phenotypes (i.e. in colon cancer cells depleted for KSR1 or EPSTI1) have relevance in an in vivo model. HCT116 for example have been used in orthotopic mouse models, with HCT116-derived tumors showing evidence of local invasion and metastasis to distant organs (lung, liver). Using the cell lines already developed by the authors, in vivo characterization of the impact of loss of KSR1 or EPSTI1 can thus be performed.</p><p>4. Related to point #3, what is the expression of KSR1 in HCEC non-transformed cells compared to HCT116/HCT15? HCECs can be induced to undergo EMT (with loss of epithelial markers and gains in mesenchymal markers, including fibronectin, vimentin, and N-cadherin). Thus, does KSR1 overexpression, or EPSTI1 overexpression in HCECs promote a full or partial EMT, and increase their invasive/metastatic behaviour in vivo? The experiments in #3 and #4 are essential to understand how at what point during the progression of colorectal cancer KSR1 expression is dysregulated, and may help design future therapeutic targeting windows.</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>This is a very strong paper that provides a thorough and definitive analysis of the role of EPSTI1 in KSR1-dependent EMT. The major question related to this study is the molecular mechanism of EPSTI1 function – which should be addressed in subsequent studies and reported in a new paper.</p><p>There is one point that the authors could address. In the Discussion section of the manuscript, the authors speculate that it is possible that KSR1 changes EPSTI1 mRNA splicing. Since the authors have RNA-seq data that could address this point, the authors should refer to thus analysis if a conclusion can be drawn. If no conclusions can be drawn, no changes to the manuscript are required.</p><p>[Editors' note: further revisions were suggested prior to acceptance, as described below.]</p><p>Thank you for resubmitting your work entitled &quot;KSR1-and ERK-dependent Translational Regulation of the Epithelial-to-Mesenchymal Transition&quot; for further consideration by <italic>eLife</italic>. Your revised article has been reviewed by two peer reviewers, and the evaluation has been overseen by Jonathan Cooper as the Senior Editor and a Reviewing Editor.</p><p>The manuscript has been improved but there are some remaining issues that need to be addressed, as outlined below:</p><p>There are 2 issues which need to be addressed.</p><p>1. In Figure 6 (supplement 1), you make the point that KD of EPSTI1 does not impact cell proliferation (in D and E). This seems to be true for SW480 cells, but it is less clear for HCT116 cells. You should provide statistics for these results.</p><p>2. You make the case that enforced expression of EPSTI1 (in the context of KSR1 KO) does not increase cell proliferation. This seems to be true for HCT116 cells, but is a lot less clear for SW480. You should provide statistics for these results.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.66608.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>1. The authors should rule out that KSR KD or KO does not impact EPSTI1 protein degradation.</p></disp-quote><p>To determine if KSR1 promotes EPSTI1 degradation, we first assessed EPSTI1 turnover in HCT116 cells following treatment with a protein synthesis inhibitor, cycloheximide (CHX) and observed that EPSTI1 has a 6-hour half-life <bold>(</bold>Figure 1—figure supplement 2D). We analyzed EPSTI1 turnover using a combination of proteasome inhibitor, MG132 and CHX in control and CRISPR-targeted KSR1 HCT116 cells (Figure 1—figure supplement 2E). EPSTI1 turnover was not sensitive to MG132 treatment in HCT116 cells lacking KSR1 expression. Therefore, in HCT116 cells, KSR1 does not mediate ubiquitin proteosome system (UPS)-mediated degradation of EPSTI1. These data support our conclusion that EPSTI1 translation is induced by KSR1. Our findings are presented in the results (lines 134-142), Figure 1—figure supplement 2D-E and the Discussion section.</p><disp-quote content-type="editor-comment"><p>2. Lines 166-167 – the authors state that KSR1-dependent translation of EPSTI1 is required for colon tumor cell transformation. First, tumor cells do not transform. They are already transformed. Second, no experiments up to this point show that EPSTI1 is required for transformation. To demonstrate this, they would need to express EPSTI1 in a normal or immortalized cell and demonstrate its ability to induce anchorage independent growth, or soft agar growth, or the ability to form tumors in mice. The experiments in figure 3 demonstrate that EPSTI1 is increased in colon cancer cell lines compared to &quot;normal&quot; cells and that KD of EPSTI1 in colon cancer cells leads to decreased viability and colony formation. Together these experiments prove that EPSTI1 is necessary for established cancer cell growth, but not transformation as stated.</p></disp-quote><p>We apologize for the incorrect use of the word ‘transformation’ in the sentence. We rectified the statement and changed the sentence in lines 184-185 to ‘These observations show that KSR1-dependent translation of ESPTI1 is required for anchorage-independent growth of colon tumor cell lines.’</p><disp-quote content-type="editor-comment"><p>3. Figure 4 – With regards to the impact of EPSTI1 KD or KO on cell migration, the authors should consider measuring the impact of EPSTI1 KD or KO on cell proliferation, since this could have a significant impact on the interpretation of the wound healing assay and Matrigel invasion assay. If there is no difference in proliferation then the authors' assertion that EPSTI1 is necessary for the migratory potential of the CRC cell lines hold true. However, if KD or KO cells are proliferating less (as supported by their previous work), then another reason the cells may appear to be closing the gap slower, or invading through Matrigel slower, is a decrease in cell cycle progression. If this is the case, the authors can still make the argument that EPSTI1 KD or KO cells move slower if they conduct realtime imaging of individual cells and track their movement (can be shown as a spider plot).</p></disp-quote><p>We agree that quantification of cell migration and invasion can be impacted significantly by cell proliferation. We confirmed that the effects observed are due solely to cell migration using two different techniques:</p><p>1. The cell migration experiments were performed using IncuCyte scratch wound analyzer. IncuCyte software is designed specifically to experimentally quantify the effects of cell migration separate from changes that occur as result of cell proliferation. Relative wound density is calculated as the percentage of spatial cell density inside the wound relative to the spatial density outside of the wound area at a given time point. The metric is designed to be zero at t=0 and 100% when cell density inside the wound is the same as the cell density outside the initial wound. The clarification on this method is included in Results section lines 190- 194 and the methods section.</p><p>2. To determine the effect of EPSTI1 on cell proliferation, we analyzed the cell growth kinetics in HCT116 and SW480 cells (Figure 6—figure supplement 1). Over a period 3 days, EPSTI1 knockdown had no effect on proliferation in comparison to control HCT116 and SW480 cells. Although, KSR1-CRISPR knockout cells grew slower that the control HCT116 and SW480 cells, EPSTI1-expression did not rescue the proliferation in these cells (Figure 6—figure supplement 1). Since cell migration was measured over 48 hours and invasion was measured for 24 hours, any effect of cell proliferation should not impact our data. Our observations are included in result section lines 238-248 and Figure 6—figure supplement 1.</p><disp-quote content-type="editor-comment"><p>4. Lines 196-198 – the authors state that &quot;the switch of E-cadherin to N-cadherin expression promotes the progression of migratory and invasive behavior orchestrated by KSR1-EPSTI1 signaling in CRC cells.&quot; This is an overstatement based on the evidence provided in Figure 5. The authors demonstrate that a switch in E-cad and N-cad are associated with migratory potential, but do not demonstrate that the switch actually promotes the progression. In order to do this, they would need to KD E-cad and/or overexpress N-cad and demonstrate that this can rescue the decrease in cell migration see in Figure 4.</p></disp-quote><p>We subjected control HCT116 cells and HCT116 cells overexpressing N-cadherin to Transwell invasion assays through Matrigel following EPSTI1 knockdown. EPSTI1 knockdown suppressed cell invasion. However, the expression of N-cadherin in cells lacking EPSTI1 was sufficient to restore invasiveness to HCT116 cells <bold>(</bold>Figure 5—figure supplement 1C-D). Our observation is consistent with previous observations that upregulation of N-cadherin enhances motility in multiple cancer cell lines (Hulit et al., 2007; Mrozik et al., 2018; Nieman et al., 1999). These results indicate that the switch of E-cadherin to N-cadherin expression promotes the progression of migratory and invasive behavior orchestrated by EPSTI1 signaling in CRC cells. The results are included in lines 218-225 and Figure 5—figure supplement 1C-D.</p><disp-quote content-type="editor-comment"><p>5. Figure 6 – Does the enforced expression of EPSTI1 increase proliferation in these cells? If so, would consider comments in point #2.</p></disp-quote><p>We analyzed the cell growth kinetics in control and EPSTI1 knockdown in HCT116 and SW480 cells (Figure 6—figure supplement 1). In comparison to the control HCT116 and SW480 cells, EPSTI1 knockdown had no effect on cell proliferation over 5 days. Our observations are included in result section lines 238-245 and Figure 6—figure supplement 1<italic>.</italic></p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>1. The data shown to support the conclusion that the regulation of EPSTI1 by KSR1 is under translational control requires clarification. Authors state in the methods that RNAseq was performed on: &quot;total RNA and RNA pooled from the polysome fraction (fractions 6-9)&quot;. According to the absorbance profile shown in figure 1A, fractions 6-9 would not correspond to efficiently translated mRNAs (i.e. bound by 3 or more ribosomes), it looks like fraction 6 is the monosome. Can the authors please clarify, as this is an important technical concern which is of course relevant to the RNA-seq analysis that the authors performed to identify EPSTI1 (and potentially other targets listed) as being under translational control. Related comment regarding Figure 1F, the comparison being made is not entirely clear, the difference between control cells and the KSR1 knock-downs seems to only be obvious in one fraction, #7, which from the absorbance profile seems to be a &quot;light fraction&quot;.</p></disp-quote><p>This is an important and attentive catch that we appreciate greatly. In our original polysome profile graphs we did not account for the dead volume between measurement of absorbance and the collection of each of the fraction which causes a delay of approximately 30 seconds. Therefore, the labeling of the graphs did not accurately correspond to the correct fraction number. We have rectified the labeling and shifted the graph to the correct fraction number. The corrected graphs are included in Figure 1A and Figure 1—figure supplement 1 includes all the individual experiments used for RNA seq analysis and the RT-qPCR for quantifying <italic>EPSTI1</italic> and <italic>HPRT</italic> mRNA.</p><p>For whatever reason, <italic>EPSTI1</italic> mRNA is predominantly located in a single polysome fraction in HCT15 cells. This was true for each of three experiments in which were isolated from HCT15 cells (Figure 1—figure supplement 1). We provide an alternate representation of that combines Figures 1F and S2C as bar graphs comparing <italic>EPSTI1</italic> and <italic>HPRT</italic> mRNA in low molecular weight fractions and high molecular weight fraction (<xref ref-type="fig" rid="sa2fig1">Author response image 1</xref>). If the reviewers believe that this graph provides better clarity, we are happy to substitute it for current Figure 1F, though our preference to show measurements within the individual fractions.</p><fig id="sa2fig1" position="float"><label>Author response image 1.</label><caption><title>RT-qPCR analysis of <italic>EPSTI1</italic> and <italic>HPRT1</italic> mRNA levels from LMW (fractions 3-5) and HMW (fractions 6-8) of the control and KSR1 knockdown HCT116 and HCT15 cells (n=3; **, P&lt;0.05; ***, P&lt;0.001; ns, non-significant).</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-66608-sa2-fig1-v3.tif"/></fig><disp-quote content-type="editor-comment"><p>2. Data with SCH772984 supports the importance of ERK1/2 activation in the regulation of EPSTI1 protein expression. However, the data that ERK1/2 inhibition alters the translation of EPSTI1 mRNA is not robust. The absorbance profiles related to the polysome fractionation done on HCT116 cells treated or not with SCH772984 are unusual, and thus the data shown in Figure 2E are in question. Related to EPSTI1 expression being under translational control, can its translation be repressed by an inhibitor of mTOR?</p></disp-quote><p>We magnified the polysome-bound fractions in the absorbance profile of HCT116 cells with or without ERK inhibitor treatment (Figure 2E) to reveal the polysome-bound fraction more clearly. The translation status of mRNAs varies temporally and between cell types from the same tissue, which can have a pronounced effect on the absorbance profiles (King and Gerber, 2016; Seimetz et al., 2019).</p><p>We tested effect of mTOR inhibition on EPSTI1 expression. mTOR inhibitor, AZD8055 inhibits mTOR with 1000-fold greater specificity than other lipid kinases (e.g., PI3 kinase) (Chresta et al., 2010). Though AZD8055 robustly inhibited phosphorylation of mTOR substrate p70 S6 kinase, its ability to decrease EPSTI1 expression in HCT116 cells was weak relative to treatment with the ERK inhibitor (Figure 2C). These observations suggest the ERK affects EPSTI1 expression via mechanisms distinct from mTOR. The results are included in lines 153-158 and Figure 2C.</p><disp-quote content-type="editor-comment"><p>3. The authors have shown data that the KSR1-dependent regulation of EPSTI1 is essential for EMT, including effects on invasion, anchorage-independent cell viability, and the cadherin switch in colon cancer cell lines depleted of KSR1 (and phenotypes are rescued with add-backs of KSR1 or EPSTI1). Missing from the manuscript is an in vivo model to show whether the observed in vitro phenotypes (i.e. in colon cancer cells depleted for KSR1 or EPSTI1) have relevance in an in vivo model. HCT116 for example have been used in orthotopic mouse models, with HCT116-derived tumors showing evidence of local invasion and metastasis to distant organs (lung, liver). Using the cell lines already developed by the authors, in vivo characterization of the impact of loss of KSR1 or EPSTI1 can thus be performed.</p></disp-quote><p>Our future directions are aimed toward extending the in vitro findings and to understand the extent to which EPSTI1 promotes metastatic behavior in colon tumors and contributes to EMT in vivo.</p><disp-quote content-type="editor-comment"><p>4. Related to point #3, what is the expression of KSR1 in HCEC non-transformed cells compared to HCT116/HCT15? HCECs can be induced to undergo EMT (with loss of epithelial markers and gains in mesenchymal markers, including fibronectin, vimentin, and N-cadherin). Thus, does KSR1 overexpression, or EPSTI1 overexpression in HCECs promote a full or partial EMT, and increase their invasive/metastatic behaviour in vivo? The experiments in #3 and #4 are essential to understand how at what point during the progression of colorectal cancer KSR1 expression is dysregulated, and may help design future therapeutic targeting windows.</p></disp-quote><p>Our previous study shows that KSR1 expression is upregulated in colon cancer cell lines when compared to the non-transformed human colon epithelial cells (HCECs) (Fisher et al., 2015). We added this statement in the Results section on lines 173-175<italic>.</italic></p><p>We tested the effect of ectopic EPSTI1 expression on invasion in non-transformed human colon epithelial cells (HCECs). We stably expressed MSCV-IRES-GFP or MSCV-IRES-EPSTI1-GFP in HCECs and subjected the cells to Transwell invasion assay through Matrigel <bold>(</bold>Figure 7B, top), and observed that EPSTI1 alone was sufficient to dramatically induce the expression of N-cadherin and double the invasive activity of HCECs (Figure 7B). These data indicate that EPSTI1 mediates N-cadherin expression to promote invasive behavior in non-transformed colon epithelial cells. The observations are included in Figure 7B and result section lines 257-263.</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>This is a very strong paper that provides a thorough and definitive analysis of the role of EPSTI1 in KSR1-dependent EMT. The major question related to this study is the molecular mechanism of EPSTI1 function – which should be addressed in subsequent studies and reported in a new paper.</p><p>There is one point that the authors could address. In the Discussion section of the manuscript, the authors speculate that it is possible that KSR1 changes EPSTI1 mRNA splicing. Since the authors have RNA-seq data that could address this point, the authors should refer to thus analysis if a conclusion can be drawn. If no conclusions can be drawn, no changes to the manuscript are required.</p></disp-quote><p>We are working toward determining how EPSTI1 alters N-cadherin or EMT-transcription factor expression to affect the EMT-like phenotype including evaluation of, a potential role for NF-κB signaling (Li et al., 2014), and an evaluation of EPSTI1 contribution cell migration, invasion and metastasis in vivo.</p><p>Our preliminary splicing analysis from the polysome profiling RNA seq data suggest that KSR1 regulates alternative splicing events, particularly exon skipping. However, the lack of sequencing depth from the RNA seq analysis does not allow us to draw detailed conclusions regarding its role in EMT-like behavior in general or EPSTI1 translation in particular. Our future directions are aimed toward determining if, and how, KSR1 regulates EPSTI1 alternative splicing and whether a preferential splice for of EPSTI1 is translated preferentially in CRC to promote the EMT-like phenotype.</p><p>References:</p><p>Chresta, C. M., Davies, B. R., Hickson, I., Harding, T., Cosulich, S., Critchlow, S. E., Vincent, J. P., Ellston, R., Jones, D., Sini, P., et al. (2010). AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Research 70, 288-298.</p><p>Fisher, K. W., Das, B., Kim, H. S., Clymer, B. K., Gehring, D., Smith, D. R., Costanzo-Garvey, D. L., Fernandez, M. R., Brattain, M. G., Kelly, D. L., et al. (2015). AMPK Promotes Aberrant PGC1β Expression To Support Human Colon Tumor Cell Survival. Molecular and Cellular Biology 35, 3866-3879.</p><p>Hulit, J., Suyama, K., Chung, S., Keren, R., Agiostratidou, G., Shan, W., Dong, X., Williams, T. M., Lisanti, M. P., Knudsen, K., and Hazan, R. B. (2007). N-cadherin signaling potentiates mammary tumor metastasis via enhanced extracellular signal-regulated kinase activation. Cancer Res 67, 3106-3116.</p><p>King, H. A., and Gerber, A. P. (2016). Translatome profiling: methods for genome-scale analysis of mRNA translation. Brief Funct Genomics 15, 22-31.</p><p>Li, T., Lu, H., Shen, C., Lahiri, S. K., Wason, M. S., Mukherjee, D., Yu, L., and Zhao, J. (2014). Identification of epithelial stromal interaction 1 as a novel effector downstream of Krüppel-like factor 8 in breast cancer invasion and metastasis. Oncogene 33, 4746-4755.</p><p>Mrozik, K. M., Blaschuk, O. W., Cheong, C. M., Zannettino, A. C. W., and Vandyke, K. (2018). N-cadherin in cancer metastasis, its emerging role in haematological malignancies and potential as a therapeutic target in cancer. BMC Cancer 18, 939.</p><p>Nieman, M. T., Prudoff, R. S., Johnson, K. R., and Wheelock, M. J. (1999). N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression. J Cell Biol 147, 631-644.</p><p>Seimetz, J., Arif, W., Bangru, S., Hernaez, M., and Kalsotra, A. (2019). Cell-type specific polysome profiling from mammalian tissues. Methods 155, 131-139.</p><p>[Editors' note: further revisions were suggested prior to acceptance, as described below.]</p><disp-quote content-type="editor-comment"><p>The manuscript has been improved but there are some remaining issues that need to be addressed, as outlined below:</p><p>There are 2 issues which need to be addressed.</p><p>1. In Figure 6 (supplement 1), you make the point that KD of EPSTI1 does not impact cell proliferation (in D and E). This seems to be true for SW480 cells, but it is less clear for HCT116 cells. You should provide statistics for these results.</p></disp-quote><p>The statistical significance, or lack thereof, for each condition in comparison to EPSTI1 KD in HCT116 and SW480 cells is now added to Figure 6—figure supplement 1. Our observations are described on lines 238-248.</p><p>Over the first 3 days, EPSTI1 knockdown had no significant effect on cell proliferation compared to control HCT116 and SW480 cells. After 7 days (9-10 doublings), EPSTI1 knockdown decreased HCT116 cell proliferation by only 16.4 %. These same initial conditions were used to measure migration over 72 hours and invasion over 24 hours. Furthermore, the IncuCyte software corrects for the influence of proliferation on migration rate. These data show that cell proliferation would not impact quantification of motility or invasion.</p><disp-quote content-type="editor-comment"><p>2. You make the case that enforced expression of EPSTI1 (in the context of KSR1 KO) does not increase cell proliferation. This seems to be true for HCT116 cells, but is a lot less clear for SW480. You should provide statistics for these results.</p></disp-quote><p>Thank you for identifying our mischaracterization of enforced EPSTI1 expression on SW480 cells. The significance, for each condition in comparison to KSR1 KO in HCT116 and SW480 cells is now added to Figure 6—figure supplement 1. These observations are described on lines 238-248.</p><p>EPSTI1 expression in KSR1 knockout cells has no significant effect on cell proliferation for 24 hours in HCT116 and SW480 cells (Figure 6—figure supplement 1A-B). However, EPSTI1 expression increased the number of invading cells by over 50% in HCT116 and over 70% in SW480 cells (Figure 6D) in that period. Although, EPSTI1 expression has a significant effect on cell proliferation over 7 days compared to KSR1 knockout cells in HCT116 and SW480 cells, EPSTI1 expression was enough to rescue the migratory potential by over 60% in KSR1 depleted HCT116 and SW480 cells within 24 hours (Figure 6C). As indicated above and in the manuscript, IncuCyte cell migration software corrects for cell proliferation. Therefore, the cell proliferation should not impact the quantification of motility.</p></body></sub-article></article>